

NATIONAL QUALITY FORUM

Measure Submission and Evaluation Worksheet 5.0

This form contains the information submitted by measure developers/stewards, organized according to NQF's measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the [submitting standards web page](#).

NQF #: 0381	NQF Project: Cancer Project
(for Endorsement Maintenance Review)	
Original Endorsement Date: Jul 31, 2008 Most Recent Endorsement Date: Jul 31, 2008	
BRIEF MEASURE INFORMATION	
De.1 Measure Title: Oncology: Treatment Summary Communication – Radiation Oncology	
Co.1.1 Measure Steward: American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)	
De.2 Brief Description of Measure: Percentage of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy who have a treatment summary report in the chart that was communicated to the physician(s) providing continuing care and to the patient within one month of completing treatment	
2a1.1 Numerator Statement: Patients who have a treatment summary* report in the chart that was communicated to the physician(s) providing continuing care and to the patient within one month of completing treatment	
Definition: *Treatment Summary: a report that includes mention of all of the following components: 1) dose delivered; 2) relevant assessment of tolerance to and progress towards the treatment goals; and 3) subsequent care plans	
Numerator Instructions: This measure should be reported once per course of radiation treatment – less than or equal to 30 days from the end of treatment.	
2a1.4 Denominator Statement: All patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy	
2a1.8 Denominator Exclusions: Documentation of a patient reason(s) for not communicating the treatment summary report to the physician(s) providing continuing care (eg, patient requests that report not be sent) and to the patient within one month of completing treatment	
Documentation of a system reason(s) for not communicating the treatment summary report to the physician(s) providing continuing care (eg, patient does not have any physician responsible for providing continuing care) and to the patient within one month of completing treatment	
1.1 Measure Type: Process	
2a1. 25-26 Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records	
2a1.33 Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Clinician : Team	
1.2-1.4 Is this measure paired with another measure? No	
De.3 If included in a composite, please identify the composite measure (title and NQF number if endorsed):	

STAFF NOTES (issues or questions regarding any criteria)
Comments on Conditions for Consideration: 2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES: Please review the evidence to

ensure the developer has addressed the measure focus.
Is the measure untested? Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> If untested, explain how it meets criteria for consideration for time-limited endorsement:
1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure (<i>check De.5</i>): 5. Similar/related endorsed or submitted measures (<i>check 5.1</i>): Other Criteria:
Staff Reviewer Name(s): Adeela Khan

1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See [guidance on evidence](#).
Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)

1a. High Impact: H M L I
(The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.)

De.4 Subject/Topic Areas (Check all the areas that apply): Cancer
De.5 Cross Cutting Areas (Check all the areas that apply): Care Coordination

1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, A leading cause of morbidity/mortality, Frequently performed procedure, Patient/societal consequences of poor quality, Severity of illness

1a.2 If "Other," please describe:

1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data):
About 1,596,670 new cancer cases are expected to be diagnosed in 2011. (1) On January 1, 2008, in the United States there were approximately 11,957,599 men and women alive who had a history of cancer of all sites -- 5,505,862 men and 6,451,737 women, [including both persons with active disease and those who are cured of their disease.] (2) Nearly two-thirds of all cancer patients will receive radiation therapy during their illness. (3) In 2011, about 571,950 Americans are expected to die of cancer, more than 1,500 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. In the US, cancer accounts for nearly 1 of every 4 deaths. (1) The 5-year relative survival rate for all cancers diagnosed between 1999 and 2006 is 68%, up from 50% in 1975-1977 (1). Based on rates from 2006-2008, 41.21% of men and women born today will be diagnosed with cancer of all sites at some time during their lifetime. (2) The National Institutes of Health estimates overall costs of cancer in 2010 at \$263.8 billion: \$102.8 billion for direct medical costs (total of all health expenditures); \$20.9 billion for indirect morbidity costs (cost of lost productivity due to illness); and \$140.1 billion for indirect mortality costs (cost of lost productivity due to premature death). (1)

1a.4 Citations for Evidence of High Impact cited in 1a.3: Quoted verbatim from the following sources:

(1) American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
(2) Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
(3) American Society for Radiation Oncology. Statistics about Radiation Therapy. Available at: <http://www.rtanswers.org/statistics/aboutradiationtherapy.aspx>. Accessed January 9, 2012.

1b. Opportunity for Improvement: H M L I
(There is a demonstrated performance gap - variability or overall less than optimal performance)

1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:
The radiation oncology treatment summary should include many details regarding the treatment course and follow-up plan, which is

critical to ensuring proper coordination of care among patient’s current and future physicians, including oncologists and primary care physicians. This is especially important for radiation oncology given that cancer patients treated with radiation typically receive multimodality treatment and many patients receive care that is fragmented among several facilities. (1)

Hayman JA. Treatment summaries in radiation oncology and their role in improving patients’ quality of care: past, present, and future. J Oncol Pract. 2009 May;5(3):108-9.

1b.2 Summary of Data Demonstrating Performance Gap (*Variation or overall less than optimal performance across providers*): **[For Maintenance – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.]**

Results of the National Initiative for Cancer Care Quality indicated that across five metropolitan statistical areas, only 50% of radiation therapy medical records for patients with breast cancer included information regarding the total dose of radiation, dose per fraction, number of fractions, and the site treated.(1)

Among physicians participating in ASTRO’s Performance Assessment for the Advancement of Radiation Oncology Treatment (PAAROT) program, an average performance rate of 92% was reported for this measure with variation among physicians ranging from 0-100%. PAAROT is a practice improvement program that enables a physician to analyze their practice and evaluate their strengths and areas for improvement.(2)

1b.3 Citations for Data on Performance Gap: **[For Maintenance – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]**

(1) Malin JL, Schneider EC, Epstein AM, Adams J, Emanuel EJ, Kahn KL. Results of the National Initiative for Cancer Care Quality: How can we improve the quality of cancer care in the United States? J Clin Oncol. 2006;24:626-634.

(2) American Society for Radiation Oncology. Performance Assessment for the Advancement of Radiation Oncology Treatment program (PAAROT). Unpublished data, 2010.

1b.4 Summary of Data on Disparities by Population Group: **[For Maintenance –Descriptive statistics for performance results for this measure by population group]**

We are not aware of any publications/evidence outlining disparities in the communication of radiation oncology treatment summaries however the National Cancer Institute and AHRQ’s National Healthcare Disparities Report has shown that disparities exist in cancer incidence and deaths by race, ethnicity and socioeconomic status. (1,2)

1b.5 Citations for Data on Disparities Cited in 1b.4: **[For Maintenance – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]**

(1) Harper S, Lynch J. Methods for Measuring Cancer Disparities: Using Data Relevant to Healthy People 2010 Cancer-Related Objectives. Cancer Control Monograph Series, No. 6. Bethesda, MD: National Cancer Institute; 2005. NIH publication 05-5777.

(2) Agency for Healthcare Research and Quality. 2010 National Healthcare Disparities Report.

<http://www.ahrq.gov/qual/nhdr10/nhdr10.pdf>. Published March 2011. Accessed January 3, 2011.

1c. Evidence (*Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.*)
Is the measure focus a health outcome? Yes No **If not a health outcome, rate the body of evidence.**

Quantity: H M L I Quality: H M L I Consistency: H M L I

Quantity	Quality	Consistency	Does the measure pass subcriterion1c?
M-H	M-H	M-H	Yes <input type="checkbox"/>
L	M-H	M	Yes <input type="checkbox"/> IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No <input type="checkbox"/>
M-H	L	M-H	Yes <input type="checkbox"/> IF potential benefits to patients clearly outweigh potential harms: otherwise No <input type="checkbox"/>
L-M-H	L-M-H	L	No <input type="checkbox"/>
Health outcome – rationale supports relationship to at least			Does the measure pass subcriterion1c?

one healthcare structure, process, intervention, or service	Yes <input type="checkbox"/> IF rationale supports relationship
<p>1c.1 Structure-Process-Outcome Relationship (<i>Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process- health outcome; intermediate clinical outcome-health outcome</i>): The measure focus is on the creation and timely completion of a treatment summary for all patients who have undergone brachytherapy or external beam radiation therapy. "The transition from active treatment to off-treatment status is pivotal to the long-term health of cancer survivors. It is a period when loss to follow-up and breakdown in the quality of care are common." Provision of a treatment summary can aid in this transition phase and improve the efficiency and coordination of care for cancer patients and survivors.(1)</p> <p>(1) Faul LA, Shibata D, Townsend I, Jacobsen PB. Improving survivorship care for patients with colorectal cancer. <i>Cancer Control</i>. 2010 Jan;17(1):35-43.</p> <p>1c.2-3 Type of Evidence (<i>Check all that apply</i>): Clinical Practice Guideline</p> <p>1c.4 Directness of Evidence to the Specified Measure (<i>State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population</i>): Clinical practice guidelines recommend the creation and subsequent communication of a radiation oncology treatment summary to the patient and other providers involved in patient care.</p> <p>The measure focus is on the creation and timely completion of a treatment summary for all patients who have undergone brachytherapy or external beam radiation therapy.</p> <p>1c.5 Quantity of Studies in the Body of Evidence (<i>Total number of studies, not articles</i>): The guideline does not address the overall quantity of studies in the body of evidence. The ACR indicates that the guidelines are based on an analysis of current literature, expert opinion, open forum commentary, and informal consensus.</p> <p>1c.6 Quality of Body of Evidence (<i>Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events</i>): The quality of the body of evidence supporting the guideline recommendation is not provided nor is it summarized through the use of a grading system.</p> <p>1c.7 Consistency of Results across Studies (<i>Summarize the consistency of the magnitude and direction of the effect</i>): The consistency of results across studies is not addressed.</p> <p>1c.8 Net Benefit (<i>Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms</i>): Timely, accurate, and effective communications are critical to quality in contemporary medical practices. Provision of a treatment summary can aid in transitioning care and improve the efficiency and coordination of care for cancer patients and survivors.</p> <p>1c.9 Grading of Strength/Quality of the Body of Evidence. Has the body of evidence been graded? No</p> <p>1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias: Although the body of evidence was not graded, each practice guideline and technical standard, representing a policy statement by the [American College of Radiology], has undergone a thorough consensus process in which it has been subjected to extensive review, requiring the approval of the Commission on Quality and Safety as well as the ACR Board of Chancellors, the ACR Council Steering Committee, and the ACR Council. The guideline was revised by the by the Guidelines and Standards Committee of the ACR Commission on Radiation Oncology which was comprised of the following individuals: : Laurie E. Gaspar, MD, MBA, FACR (Principal Reviewer); Seth A. Rosenthal, MD, FACR, Chair Nathan Bittner, MD; Cassandra S. Foens, MD, FACR; Beth A. Erickson-Wittmann, MD, FACR; James M. Galvin, DSc; Brian J.</p>	

Goldsmith, MD; Alan C. Hartford, MD, PhD; Maria D. Kelly, MB, BCH, FACR; John S. Kent, MS, FACR; Tariq A. Mian, PhD, FACR; Janelle L. Park, MD; Louis Potters, MD, FACR; Rachel A. Rabinovitch, MD
Michael A. Samuels, MD, FACR; Steven K. Seung, MD, PhD; Gregory M. Videtic, MD, CM; Maria T. Vlachaki, MD, PhD, MBA, FACR; Albert L. Blumberg, MD, FACR, Chair, Commission

1c.11 System Used for Grading the Body of Evidence: **Other**

1c.12 If other, identify and describe the grading scale with definitions: **None; the body of evidence was not graded.**

1c.13 Grade Assigned to the Body of Evidence: **Not applicable**

1c.14 Summary of Controversy/Contradictory Evidence: **No controversy of contradictory evidence reported.**

1c.15 Citations for Evidence other than Guidelines (*Guidelines addressed below*):

1c.16 Quote verbatim, the specific guideline recommendation (Including guideline # and/or page #):

A summary should be generated that accurately describes the treatment process, the doses delivered to the target/tumor volume and other key organs, relevant assessment of tolerance to and progress towards the treatment goals, and subsequent care plans. The style will reflect the radiation oncologist's individual practice convention and the referral provider's needs. Some may use a standardized reporting format, others a more descriptive personal letter. Narrative explanations of highly technical aspects of the treatment may be included in the treatment summary when considered to be informative, but these, at a minimum, should be in the permanent record.(1)

Through written reports and direct communication, radiation oncologists convey their knowledge regarding patient care, services provided, and quality of care to others involved in the care of the patient. This communication should involve primary care physicians, medical oncologists, surgeons, and other members of the radiation oncology treatment team (such as radiation therapists, dosimetrists, physicists, nurses, tumor registrars, and quality assurance personnel) [Radiation oncology activities] should be communicated, at a minimum, by an initial consultation, a treatment (completion) summary, and a follow-up evaluation. There remains no substitute for direct, timely personal communication on all clinically relevant matters with the patient, the patient's family or support system, and physicians or other health care professionals.(1)

1c.17 Clinical Practice Guideline Citation: (1) ACR Practice Guideline for Communication: Radiation Oncology. Reston, VA: American College of Radiology. Res. 7 – 2009. Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/Comm_Radiation_Oncology.pdf. Accessed January 9, 2012.

1c.18 National Guideline Clearinghouse or other URL:

http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/Comm_Radiation_Oncology.pdf

1c.19 Grading of Strength of Guideline Recommendation. Has the recommendation been graded? **No**

1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:

1c.21 System Used for Grading the Strength of Guideline Recommendation: **Other**

1c.22 If other, identify and describe the grading scale with definitions: **None; the guideline recommendation was not graded.**

1c.23 Grade Assigned to the Recommendation: **Not applicable**

1c.24 Rationale for Using this Guideline Over Others: **It is the PCPI policy to use guidelines, which are evidence-based, applicable to physicians and other health-care providers, and developed by a national specialty organization or government agency. In addition, the PCPI has now expanded what is acceptable as the evidence base for measures to include documented quality**

improvement (QI) initiatives or implementation projects that have demonstrated improvement in quality of care.

Based on the NQF descriptions for rating the evidence, what was the developer's assessment of the quantity, quality, and consistency of the body of evidence?

1c.25 Quantity: **Moderate** 1c.26 Quality: **Moderate** 1c.27 Consistency: **Moderate**

Was the threshold criterion, *Importance to Measure and Report*, met?

(1a & 1b must be rated moderate or high and 1c yes) Yes No

Provide rationale based on specific subcriteria:

For a new measure if the Committee votes NO, then STOP.

For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.

2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. **(evaluation criteria)**

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See [guidance on measure testing](#).

S.1 **Measure Web Page** (In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained). Do you have a web page where current detailed specifications for this measure can be obtained? **Yes**

S.2 If yes, provide web page URL: www.physicianconsortium.org

2a. RELIABILITY. Precise Specifications and Reliability Testing: H M L I

2a1. Precise Measure Specifications. (The measure specifications precise and unambiguous.)

2a1.1 **Numerator Statement** (Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome):

Patients who have a treatment summary* report in the chart that was communicated to the physician(s) providing continuing care and to the patient within one month of completing treatment

Definition: *Treatment Summary: a report that includes mention of all of the following components: 1) dose delivered; 2) relevant assessment of tolerance to and progress towards the treatment goals; and 3) subsequent care plans

Numerator Instructions: This measure should be reported once per course of radiation treatment – less than or equal to 30 days from the end of treatment.

2a1.2 **Numerator Time Window** (The time period in which the target process, condition, event, or outcome is eligible for inclusion):
 <= one month after completion of therapy during measurement period

2a1.3 **Numerator Details** (All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses:
 For EHR:

eSpecification currently under development. Data elements (using Quality Data Model) required for the measure are attached.

For Claims/Administrative:

Report CPT Category II code: 5020F - Treatment summary report communicated to physician(s) managing continuing care and to the patient within one month of completing treatment

2a1.4 **Denominator Statement** (Brief, narrative description of the target population being measured):

All patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam radiation therapy

2a1.5 Target Population Category (Check all the populations for which the measure is specified and tested if any): [Adult/Elderly Care, Children's Health](#)

2a1.6 Denominator Time Window (The time period in which cases are eligible for inclusion):
[Each course of brachytherapy or external beam radiation therapy within 12 consecutive months](#)

2a1.7 Denominator Details (All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):

For EHR:

[eSpecification currently under development. Data elements \(using Quality Data Model\) required for the measure are attached.](#)

For Claims/Administrative:

[CPT® codes for external beam radiation therapy, weekly management or brachytherapy:](#)

[77427, 77431, 77432, 77435, 77470, 77761, 77762, 77763, 77776, 77777, 77778, 77785, 77786, 77787](#)

[AND](#)

[ICD-9-CM diagnosis codes: See Attached Code List \(Appendix A in attachment\)](#)

[ICD-10-CM diagnosis codes: See Attached Code List \(Appendix A in attachment\)](#)

2a1.8 Denominator Exclusions (Brief narrative description of exclusions from the target population):

[Documentation of a patient reason\(s\) for not communicating the treatment summary report to the physician\(s\) providing continuing care \(eg, patient requests that report not be sent\) and to the patient within one month of completing treatment](#)

[Documentation of a system reason\(s\) for not communicating the treatment summary report to the physician\(s\) providing continuing care \(eg, patient does not have any physician responsible for providing continuing care\) and to the patient within one month of completing treatment](#)

2a1.9 Denominator Exclusion Details (All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):

[The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include patient \(eg, patient requests that report not be sent\) or system reason\(s\) \(eg, patient does not have any physician responsible for providing continuing care\) for not communicating the treatment summary report to the physician\(s\) providing continuing care and to the patient within one month of completing treatment. Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients' medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician's exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional details by data source are as follows:](#)

For EHR:

[eSpecification currently under development. Data elements \(using Quality Data Model\) required for the measure are attached.](#)

For Claims/Administrative:

[Documentation of patient reason\(s\) for not having a treatment summary report in the chart that was communicated to the physician\(s\) providing continuing care \(eg, patient requests that report not be sent\) and to the patient within one month of completing treatment](#)

- [• Append modifier to CPT Category II code: 5020F-2P](#)

[Documentation of system reason\(s\) for not having a treatment summary report in the chart that was communicated to the physician\(s\) providing continuing care \(eg, patient does not have any physician responsible for providing continuing care\) and to the](#)

patient within one month of completing treatment
 • Append modifier to CPT Category II code: 5020F-3P

2a1.10 Stratification Details/Variables (All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses):

We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

2a1.11 Risk Adjustment Type (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13): No risk adjustment or risk stratification **2a1.12 If "Other," please describe:**

2a1.13 Statistical Risk Model and Variables (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):

None

2a1.14-16 Detailed Risk Model Available at Web page URL (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

2a1.17-18. Type of Score: [Rate/proportion](#)

2a1.19 Interpretation of Score (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score): [Better quality = Higher score](#)

2a1.20 Calculation Algorithm/Measure Logic(Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.):

To calculate performance rates:

- 1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).
- 2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.
- 3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator
- 4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified [for this measure: patient reason(s) (eg, patient requests that report not be sent) or system reason(s)(eg, patient does not have any physician responsible for providing continuing care)]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. --Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.

2a1.21-23 Calculation Algorithm/Measure Logic Diagram URL or attachment:

[Attachment](#)

[AMA-PCPI_Measure Calculation-Standard Measures-634620643896118889.pdf](#)

2a1.24 Sampling (Survey) Methodology. If measure is based on a sample (or survey), provide instructions for obtaining the

sample, conducting the survey and guidance on minimum sample size (response rate):

Not applicable. The measure does not require sampling or a survey.

2a1.25 Data Source (Check all the sources for which the measure is specified and tested). If other, please describe:
[Administrative claims](#), [Electronic Clinical Data](#), [Electronic Clinical Data : Electronic Health Record](#), [Electronic Clinical Data : Registry](#), [Paper Records](#)

2a1.26 Data Source/Data Collection Instrument (Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.): [Not Applicable](#)

2a1.27-29 Data Source/data Collection Instrument Reference Web Page URL or Attachment:

2a1.30-32 Data Dictionary/Code Table Web Page URL or Attachment:

[Attachment](#)

[AMA-PCPI_0381_DataElements_AppendixA.pdf](#)

2a1.33 Level of Analysis (Check the levels of analysis for which the measure is specified and tested): [Clinician : Group/Practice](#), [Clinician : Individual](#), [Clinician : Team](#)

2a1.34-35 Care Setting (Check all the settings for which the measure is specified and tested): [Ambulatory Care : Clinician Office](#), [Other:Radiation Oncology Dept/Clinic](#)

2a2. Reliability Testing. (Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.)

2a2.1 Data/Sample (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

[PCPI Testing Project](#)

Five practice sites representing various types, locations and sizes were identified to participate in testing the PCPI/ASCO/ASTRO-developed performance measures.

o [Site A: hospital, multi-practice sites in urban, rural and suburban settings; 21 physicians; average 9600 oncology/prostate cancer patient visits per month for MD/NP assessment, chemotherapy; submitted PQRS claims for one measure and utilized a full-fledged EHR.](#)

o [Site B: physician owned private practice, suburban setting; 4 physicians; average 48 oncology/prostate cancer patients seen per day; submitted PQRS claims for one measure and utilized paper medical records.](#)

o [Site C: physician owned private practice, urban setting; 41 physicians; average 2500 oncology/prostate cancer patients seen per month; submitted PQRS claims for two measures and utilized a full-fledged EHR.](#)

o [Site D: academic, suburban setting; 9 physicians; average 240 oncology/prostate cancer patients seen per month; submitted PQRS claims for one measure and utilized paper and EHR.](#)

o [Site E: academic, urban setting; 14 physicians; average 250 oncology/prostate cancer patients seen per month; collected PQRS data on 3 measures and utilized a full-fledged EHR.](#)

- [The measurement period \(data collected from patients seen\) was 1/1/2010 through 12/31/2010.](#)

- [Chart abstraction was performed between 8/8/2011 and 11/3/2011.](#)

2a2.2 Analytic Method (Describe method of reliability testing & rationale):

[PCPI Testing Project](#)

[Data abstracted from patient records were used to calculate inter-rater reliability for the measure.](#)

[132 patient records were reviewed.](#)

[Data analysis included:](#)

- [Percent agreement; and](#)
- [Kappa statistic to adjust for chance agreement.](#)

2a2.3 Testing Results (*Reliability statistics, assessment of adequacy in the context of norms for the test conducted*):

PCPI Testing Project

N, % Agreement, Kappa (95% Confidence Interval)

Overall Reliability: 132, 100.0%, Kappa is noncalculable*

Denominator Reliability: 132, 100.0%, Kappa is noncalculable*

Numerator Reliability: 132, 100.0%, Kappa is noncalculable*

Exception Reliability: 132, 100.0%, Kappa is noncalculable*

This measure demonstrates perfect reliability, as shown in results from the above analysis.

*Kappa Statistics cannot be calculated because of complete agreement. Confidence intervals cannot be calculated because to do so would involve dividing by zero which cannot be done.

2b. VALIDITY. Validity, Testing, including all Threats to Validity: H M L I

2b1.1 Describe how the measure specifications (*measure focus, target population, and exclusions*) **are consistent with the evidence cited in support of the measure focus** (*criterion 1c*) **and identify any differences from the evidence:**

Clinical practice guidelines recommend the creation and subsequent communication of a radiation oncology treatment summary to the patient and other providers involved in patient care.

The measure focus is on the creation and timely completion of a treatment summary for all patients who have undergone brachytherapy or external beam radiation therapy.

2b2. Validity Testing. (*Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.*)

2b2.1 Data/Sample (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

An expert panel was used to assess face validity of the measure. This panel consisted of the following 31 members, with representation from a number of specialties including oncology, radiation oncology, surgical oncology, urology, gastroenterology, hematology, pathology, colon and rectal surgery, otolaryngology, and pain medicine.

Patricia Ganz, MD (Co-Chair) (Clinical Oncology) Los Angeles, CA
 James Hayman, MD (Co-Chair) (Radiation Oncology) Ann Arbor MI
 Joseph Bailes, MD (Clinical Oncology) The Woodlands, TX
 Nancy Baxter, MD, PhD (Colorectal Surgery) Toronto, Ontario Canada
 Joel V. Brill, MD (Gastroenterology) Phoenix, AZ
 Steven B. Clauser, PhD (Outcomes Research) Bethesda, MD
 Charles Cleeland, PhD (Oncology) Houston, TX
 J. Thomas Cross, Jr. MD, MPH (Oncology) Colorado Springs, CO
 Chaitanya R. Divgi, MD (Nuclear Medicine) Philadelphia, PA
 Stephen B. Edge, MD (Surgical Oncology) Buffalo, NY
 Patrick L. Fitzgibbons, MD (Oncology) Fullerton, CA
 Myron Goldsmith, MD (Oncology) Huntington Beach, CA
 Joel W. Goldwein, MD (Oncology) Merion Station, PA
 Alecia Hathaway, MD, MPH (Oncology) Fort Worth, TX
 Kevin P. Hubbard, DO (Oncology) Kansas City, MO
 Nora Janjan, MD, MPSA (Radiation Oncology) Houston, TX
 Maria Kelly, MB, BCh (Radiation Oncology) Earlysville, VA
 Wayne Koch, MD (Head and Neck surgery) Columbia, MD
 Andre Konski, MD (Radiation Oncology) Philadelphia, PA
 Len Lichtenfeld, MD (Oncology) Atlanta, GA
 Norman J. Marcus, MD (Anesthesiology and Psychiatry) New York, NY
 Catherine Miyamoto, RN, BSN (Oncology) Grand Forks, ND
 Michael Neuss, MD (Oncology, Hematology) Cincinnati, OH
 David F. Penson, MD, MPH (Urology) Nashville, TN

Louis Potters, MD (Radiation Oncology) New Hyde Park, NY
John M. Rainey, MD (Medical Oncology) Lafayette, LA
Christopher M. Rose, MD (Radiation Therapy) Beverly Hills, El Segundo, CA
Lee Smith, MD (Oncology) Washington, DC
Lawrence A. Solberg, MD, PhD (Oncology) Jacksonville, FL
Paul E. Wallner, MD (Radiation Oncology) Willingboro, NJ
J. Frank Wilson, MD (Radiation Oncology) Milwaukee, WI

2b2.2 Analytic Method (*Describe method of validity testing and rationale; if face validity, describe systematic assessment*):

All PCPI performance measures are assessed for content validity by a panel of expert work group members during the development process. Additional input on the content validity of draft measures is obtained through a 30-day public comment period and by also soliciting comments from a panel of consumer, purchaser, and patient representatives convened by the PCPI specifically for this purpose. All comments received are reviewed by the expert work group and the measures adjusted as needed. Other external review groups (eg, focus groups) may be convened if there are any remaining concerns related to the content validity of the measures.

The expert panel was used to assess face validity of the measure. This panel consisted of 31 members, with representation from the following specialties: oncology, radiation oncology, surgical oncology, urology, gastroenterology, hematology, pathology, colon and rectal surgery, otolaryngology, and pain medicine.

The aforementioned panel was asked to rate their agreement with the following statement:

The scores obtained from the measure as specified will accurately differentiate quality across providers.

Scale 1-5, where 1=Strongly Disagree; 3=Neither Disagree nor Agree; 5=Strongly Agree

2b2.3 Testing Results (*Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment*):

The results of the expert panel rating of the validity statement were as follows: N = 18; Mean rating = 3.6.

Percentage in the top two categories (4 and 5): 94.44%

Frequency Distribution of Ratings

1-	0
2-	1
3-	0
4-	8
5-	9

POTENTIAL THREATS TO VALIDITY. (*All potential threats to validity were appropriately tested with adequate results.*)

2b3. Measure Exclusions. (*Exclusions were supported by the clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.*)

2b3.1 Data/Sample for analysis of exclusions (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

PCPI Testing Project

- 132 patient records were reviewed for this measure.
- The measurement period (data collected from patients seen) was 1/1/2010 through 12/31/2010.
- Chart abstraction was performed between 8/8/2011 and 11/3/2011.

2b3.2 Analytic Method (*Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference*):

Exceptions were analyzed for frequency and variability across providers.

2b3.3 Results (Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses):

PCPI Testing Project

N, % Agreement, Kappa (95% Confidence Interval)

Exception Reliability: 132, 100.0%, Kappa is noncalculable*

This measure demonstrates perfect reliability, as shown in the results from the above analysis.

The exception rate for this measure is 0%.

*Kappa Statistics cannot be calculated because of complete agreement. Confidence intervals cannot be calculated because to do so would involve dividing by zero which cannot be done.

2b4. Risk Adjustment Strategy. (For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.)

2b4.1 Data/Sample (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

This measure is not risk adjusted.

2b4.2 Analytic Method (Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables):

This measure is not risk adjusted.

2b4.3 Testing Results (Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot, and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata):

Not Applicable

2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of adjustment: Not Applicable.

2b5. Identification of Meaningful Differences in Performance. (The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.)

2b5.1 Data/Sample (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

PCPI Testing Project

- 132 patient records were reviewed for this measure.

- The measurement period (data collected from patients seen) was 1/1/2010 through 12/31/2010.

- Chart abstraction was performed between 8/8/2011 and 11/3/2011.

2b5.2 Analytic Method (Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance):

PCPI Testing Project

Data analysis performed on the measure included:

Average measure performance rate overall and by site, performance rate range by site and overall standard deviation for the measure.

2b5.3 Results (Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):

PCPI Testing Project

Average Measure performance rate without exceptions: N= 132 Mean = 89.4 % Standard Deviation= 0.3091

The performance rate by site is as follows, where n is the number of performance events by site:

A 0.8666 (n= 30)

B 0.9500 (n= 20)
 D 1.0000 (n= 30)
 E 0.8269 (n= 52)

The performance rate range is .1731. Although this study captured performance on 132 events, the data were not captured at the physician level, restricting reporting of variation in performance to the organization level only. Additionally, we are unable to present a meaningful calculation of variation in performance across organizations due to the small sample size of sites (n=4) in this study.

2b6. Comparability of Multiple Data Sources/Methods. (If specified for more than one data source, the various approaches result in comparable scores.)

2b6.1 Data/Sample (Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

This test was not performed for this measure.

2b6.2 Analytic Method (Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure):

This test was not performed for this measure.

2b6.3 Testing Results (Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted):

This test was not performed for this measure.

2c. Disparities in Care: H M L I NA (If applicable, the measure specifications allow identification of disparities.)

2c.1 If measure is stratified for disparities, provide stratified results (Scores by stratified categories/cohorts): We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.

2c.2 If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:

The PCPI advocates that performance measure data should, where possible, be stratified by race, ethnicity, and primary language to assess disparities and initiate subsequent quality improvement activities addressing identified disparities, consistent with recent national efforts to standardize the collection of race and ethnicity data. A 2008 NQF report endorsed 45 practices including stratification by the aforementioned variables. (1) A 2009 IOM report “recommends collection of the existing Office of Management and Budget (OMB) race and Hispanic ethnicity categories as well as more fine-grained categories of ethnicity (referred to as granular ethnicity and based on one’s ancestry) and language need (a rating of spoken English language proficiency of less than very well and one’s preferred language for health-related encounters).” (2)

References:

(1) National Quality Forum Issue Brief (No.10). Closing the Disparities Gap in Healthcare Quality with Performance Measurement and Public Reporting. Washington, DC: NQF, August 2008.

(2) Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement. March 2010. AHRQ Publication No. 10-0058-EF. Agency for Healthcare Research and Quality, Rockville, MD. Available at: <http://www.ahrq.gov/research/iomracereport>. Accessed May 25, 2010.

2.1-2.3 Supplemental Testing Methodology Information:

Steering Committee: Overall, was the criterion, *Scientific Acceptability of Measure Properties*, met?

(Reliability and Validity must be rated moderate or high) Yes No

Provide rationale based on specific subcriteria:

If the Committee votes No, STOP

3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

C.1 Intended Purpose/ Use (Check all the purposes and/or uses for which the measure is intended): Professional Certification or Recognition Program, Public Reporting, Quality Improvement (Internal to the specific organization)

3.1 Current Use (Check all that apply; for any that are checked, provide the specific program information in the following questions): Public Reporting, Professional Certification or Recognition Program, Quality Improvement (Internal to the specific organization)

3a. Usefulness for Public Reporting: H M L I
(The measure is meaningful, understandable and useful for public reporting.)

3a.1. Use in Public Reporting - disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [**For Maintenance** – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]

This measure has been proposed for use in the PQRS program, but it not currently part of that program.

The PCPI believes that the reporting of participation information is a beneficial first step on a trajectory toward the public reporting of performance results, which is appropriate since the measure has been tested and the reliability of the performance data has been validated. Continued NQF endorsement will facilitate our ongoing progress toward this public reporting objective.

3a.2. Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: The PCPI believes that the reporting of participation information is a beneficial first step on a trajectory toward the public reporting of performance results, which is appropriate since the measure has been tested and the reliability of the performance data has been validated. Continued NQF endorsement will facilitate our ongoing progress toward this public reporting objective.

3.2 Use for other Accountability Functions (payment, certification, accreditation). If used in a public accountability program, provide name of program(s), locations, Web page URL(s): This measure may be used in a Maintenance of Certification program, including the following current initiatives:

PAAROT is ASTRO's Maintenance of Certification program that is recognized by the American Board of Radiology (ABR) as a Type 2 PQI project in partial fulfillment of the MOC requirements.

3b. Usefulness for Quality Improvement: H M L I
(The measure is meaningful, understandable and useful for quality improvement.)

3b.1. Use in QI. If used in quality improvement program, provide name of program(s), locations, Web page URL(s): [**For Maintenance** – If not used for QI, indicate the reasons and describe progress toward using performance results for improvement].

This measure is currently being used in ASTRO's Performance Assessment for the Advancement of Radiation Oncology Treatment (PAAROT) program. PAAROT is a practice improvement program that enables a physician to analyze their practice and evaluate their strengths and areas for improvement. The data is collected at the physician level and involves periodic chart review of the measures included in the program.

All PCPI measures are suitable for use in quality improvement initiatives and are made freely available on the PCPI website and through the implementation efforts of medical specialty societies and other PCPI members. The PCPI strongly encourages the use of its measures in QI initiatives and seeks to provide information on such initiatives to PCPI members.

3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement. If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results:
 The PCPI believes that the use of PCPI measures in quality improvement initiatives is a beneficial way to gather scientific data with which to improve physician performance. This is appropriate since the measure has been tested and the reliability of the performance data has been validated. NQF endorsement will facilitate our ongoing progress toward this quality improvement objective.

Overall, to what extent was the criterion, *Usability*, met? H M L I

Provide rationale based on specific subcriteria:

4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes: H M L I

4a.1-2 How are the data elements needed to compute measure scores generated? (Check all that apply).

Data used in the measure are:

generated by and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition

4b. Electronic Sources: H M L I

4b.1 Are the data elements needed for the measure as specified available electronically (Elements that are needed to compute measure scores are in defined, computer-readable fields): ALL data elements in electronic health records (EHRs)

4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:

4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences: H M L I

4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:

We are not aware of any unintended consequences related to this measurement.

4d. Data Collection Strategy/Implementation: H M L I

A.2 Please check if either of the following apply (regarding proprietary measures):

4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues (e.g., fees for use of proprietary measures):

This measure was found to be reliable and feasible for implementation.

Overall, to what extent was the criterion, *Feasibility*, met? H M L I

Provide rationale based on specific subcriteria:

OVERALL SUITABILITY FOR ENDORSEMENT

Does the measure meet all the NQF criteria for endorsement? Yes No

Rationale:

If the Committee votes No, STOP.

If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.

5. COMPARISON TO RELATED AND COMPETING MEASURES

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are

compared to address harmonization and/or selection of the best measure before a final recommendation is made.
5.1 If there are related measures (<i>either same measure focus or target population</i>) or competing measures (<i>both the same measure focus and same target population</i>), list the NQF # and title of all related and/or competing measures:
5a. Harmonization
5a.1 If this measure has EITHER the same measure focus OR the same target population as NQF-endorsed measure(s) : Are the measure specifications completely harmonized?
5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:
5b. Competing Measure(s)
5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s): Describe why this measure is superior to competing measures (<i>e.g., a more valid or efficient way to measure quality</i>); OR provide a rationale for the additive value of endorsing an additional measure. (<i>Provide analyses when possible</i>):

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner): American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) , 515 N. State Street, Chicago, Illinois, 60654
Co.2 Point of Contact: Mark S., Antman, DDS, MBA, Director, Measure Development Operations Performance Improvement, mark.antman@ama-assn.org, 312-464-5056-
Co.3 Measure Developer if different from Measure Steward: American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI) , 515 N. State Street, Chicago, Illinois, 60654
Co.4 Point of Contact: Samantha, Tierney, MPH, samantha.tierney@ama-assn.org, 312-464-5524-
Co.5 Submitter: Mark S., Antman, DDS, MBA, Director, Measure Development Operations Performance Improvement, mark.antman@ama-assn.org, 312-464-5056- , American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)
Co.6 Additional organizations that sponsored/participated in measure development: The measure set was developed in collaboration with the American Society of Clinical Oncology and the American Society for Radiation Oncology.
Co.7 Public Contact: Mark S., Antman, DDS, MBA, Director, Measure Development Operations Performance Improvement, mark.antman@ama-assn.org, 312-464-5056- , American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)

ADDITIONAL INFORMATION

<p>Workgroup/Expert Panel involved in measure development</p> <p>Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.</p> <p>Patricia Ganz, MD (Co-Chair) James Hayman, MD (Co-Chair) Joseph Bailes, MD Nancy Baxter, MD, PhD Joel V. Brill, MD</p>
--

Steven B. Clauser, PhD
 Charles Cleeland, PhD
 J. Thomas Cross, Jr. MD, MPH
 Chaitanya R. Divgi, MD
 Stephen B. Edge, MD
 Patrick L. Fitzgibbons, MD
 Myron Goldsmith, MD
 Joel W. Goldwein, MD
 Alecia Hathaway, MD, MPH
 Kevin P. Hubbard, DO
 Nora Janjan, MD, MPSA
 Maria Kelly, MB, BCh
 Wayne Koch, MD
 Andre Konski, MD
 Len Lichtenfeld, MD
 Norman J. Marcus, MD
 Catherine Miyamoto, RN, BSN
 Michael Neuss, MD
 David F. Penson, MD, MPH
 Louis Potters, MD
 John M. Rainey, MD
 Christopher M. Rose, MD
 Lee Smith, MD
 Lawrence A. Solberg, MD, PhD
 Paul E. Wallner, MD
 J. Frank Wilson, MD
 Rodger Winn, MD

PCPI measures are developed through cross-specialty, multi-disciplinary work groups. All medical specialties and other health care professional disciplines participating in patient care for the clinical condition or topic under study are invited to participate as equal contributors to the measure development process. In addition, the PCPI strives to include on its work groups individuals representing the perspectives of patients, consumers, private health plans, and employers. This broad-based approach to measure development ensures buy-in on the measures from all stakeholders and minimizes bias toward any individual specialty or stakeholder group. All work groups have at least two co-chairs who have relevant clinical and/or measure development expertise and who are responsible for ensuring that consensus is achieved and that all perspectives are voiced.

Ad.2 If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for adapting the original measure and any work with the original measure steward:

Measure Developer/Steward Updates and Ongoing Maintenance

Ad.3 Year the measure was first released: 2007

Ad.4 Month and Year of most recent revision: 12, 2011

Ad.5 What is your frequency for review/update of this measure? Coding/specifications updates occur annually. See additional information below.

Ad.6 When is the next scheduled review/update for this measure? 2012

Ad.7 Copyright statement: Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement™ (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2007 American Medical Association. All Rights Reserved

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Ad.8 Disclaimers: See copyright statement above.

Ad.9 Additional Information/Comments: The PCPI has a formal measurement review process that stipulates regular (usually on a three-year cycle, when feasible) review of the measures. The process can also be activated if there is a major change in scientific evidence, results from testing or other issues are noted that materially affect the integrity of the measure.

Date of Submission (MM/DD/YY): 10/03/2011

Data Elements for PCPI eSpecification

[0381] Oncology: Treatment Summary Communication – Radiation Oncology

QDM* Standard Category	QDM* Data Type	Standard Terminology (Value Set OID)	Constraints	Value Set Name	Value of Data Element	Data Source	Comments/Rationale
Measure Timing	N/A	N/A	TBD by measure implementer	Measurement Start Date			
Measure Timing	N/A	N/A	TBD by measure implementer	Measurement End Date			
Individual Characteristic	Patient Characteristic	Gender HL7 Value Set (2.16.840.1.113883.1.11.1)	during measurement period	Gender		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Race CDC Value Set (2.16.840.1.114222.4.11.836)	during measurement period	Race		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)	during measurement period	Ethnicity		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)	during measurement period	Payer		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	Primary spoken language (2.16.840.1.114222.4.11.831)	during measurement period	Preferred Language		• Electronic Health Record (EHR)	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	LOINC (2.16.840.1.113883.3.560.100.4)	starts before the start of measurement period	Birth date		• Electronic Health Record (EHR)	
Individual Characteristic	Patient Characteristic	Calculated	starts before the start of measurement period	Age	All ages	• Electronic Health Record (EHR)	For this measure, there are no restrictions on age for denominator inclusion. Collected for possible stratification of data.
Condition / Diagnosis / Problem	Diagnosis, Active	ICD-9-CM, ICD-10-CM, SNOMED-CT (2.16.840.1.113883.3.526.03.1010)	starts before or during measurement period	Cancer		• Electronic Health Record (EHR)	This value set will include all malignancies and all with uncertain or unspecified behavior.
Procedure	Procedure, Performed	CPT, SNOMED-CT (TBD)	ends during measurement period	Radiation Treatment Management		• Electronic Health Record (EHR)	The numerator action is to be performed for patients who completed (ended) treatment; therefore our denominator needs to be limited to those who's treatment ended during the measurement period.
Procedure	Procedure, Performed	CPT, SNOMED-CT (TBD)	ends during measurement period	Brachytherapy		• Electronic Health Record (EHR)	The numerator action is to be performed for patients who completed (ended) treatment; therefore our denominator needs to be limited to those who's treatment ended during the measurement period.
Procedure	Procedure, Performed	CPT, SNOMED-CT (2.16.840.1.113883.3.526.03.1131)	ends during measurement period	External Beam Radiotherapy		• Electronic Health Record (EHR)	The numerator action is to be performed for patients who completed (ended) treatment; therefore our denominator needs to be limited to those who's treatment ended during the measurement period.
Communication	Communication: Provider to Patient [Attribute.Result]	SNOMED-CT (TBD)	starts after the end of [Procedure, Performed: Brachytherapy] <= 30 days; OR starts after the end of [Procedure, Performed: External Beam Radiotherapy] <= 30 days	Treatment Summary [Radiation Dose]		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Patient [Attribute.Result]	SNOMED-CT (TBD)	starts after the end of [Procedure, Performed: Brachytherapy] <= 30 days; OR starts after the end of [Procedure, Performed: External Beam Radiotherapy] <= 30 days	Treatment Summary [Progress]		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Patient [Attribute.Result]	SNOMED-CT (TBD)	starts after the end of [Procedure, Performed: Brachytherapy] <= 30 days; OR starts after the end of [Procedure, Performed: External Beam Radiotherapy] <= 30 days	Treatment Summary [Care Plan]		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Patient [Attribute.Result]	SNOMED-CT (TBD)	starts after the end of [Procedure, Performed: Brachytherapy] <= 30 days; OR starts after the end of [Procedure, Performed: External Beam Radiotherapy] <= 30 days	Treatment Summary [Radiation Dose]		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Patient [Attribute.Result]	SNOMED-CT (TBD)	starts after the end of [Procedure, Performed: Brachytherapy] <= 30 days; OR starts after the end of [Procedure, Performed: External Beam Radiotherapy] <= 30 days	Treatment Summary [Progress]		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Patient [Attribute.Result]	SNOMED-CT (TBD)	starts after the end of [Procedure, Performed: Brachytherapy] <= 30 days; OR starts after the end of [Procedure, Performed: External Beam Radiotherapy] <= 30 days	Treatment Summary [Care Plan]		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Provider [Negation Rationale]	SNOMED-CT (2.16.840.1.113883.3.526.03.1008)	during measurement period	Patient Reason		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Patient [Negation Rationale]	SNOMED-CT (2.16.840.1.113883.3.526.03.1008)	during measurement period	Patient Reason		• Electronic Health Record (EHR)	
Preference	Patient Preference	SNOMED-CT (TBD)	starts before or during measurement period	Do Not Release Information		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Provider [Negation Rationale]	SNOMED-CT (2.16.840.1.113883.3.526.03.1009)	during measurement period	System Reason		• Electronic Health Record (EHR)	
Communication	Communication: Provider to Patient [Negation Rationale]	SNOMED-CT (2.16.840.1.113883.3.526.03.1009)	during measurement period	System Reason		• Electronic Health Record (EHR)	
Individual Characteristic	Patient Characteristic	SNOMED-CT (TBD)	starts before or during measurement period	No Primary Care Provider		• Electronic Health Record (EHR)	

*The Quality Data Model (QDM), Version 2.1, was developed by National Quality Forum (NQF).

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
140.0	Malignant neoplasm of upper lip, vermilion border	C00.0	Malignant neoplasm of external upper lip
140.1	Malignant neoplasm of lower lip, vermilion border	C00.1	Malignant neoplasm of external lower lip
140.3	Malignant neoplasm of upper lip, inner aspect	C00.2	Malignant neoplasm of external lip, unspecified
140.4	Malignant neoplasm of lower lip, inner aspect	C00.3	Malignant neoplasm of upper lip, inner aspect
140.5	Malignant neoplasm of lip, unspecified, inner aspect	C00.4	Malignant neoplasm of lower lip, inner aspect
140.6	Malignant neoplasm of commissure of lip	C00.5	Malignant neoplasm of lip, unspecified, inner aspect
140.8	Malignant neoplasm of other sites of lip	C00.6	Malignant neoplasm of commissure of lip, unspecified
140.9	Malignant neoplasm of lip, unspecified, vermilion border	C00.8	Malignant neoplasm of overlapping sites of lip
141.0	Malignant neoplasm of base of tongue	C00.9	Malignant neoplasm of lip, unspecified
141.1	Malignant neoplasm of dorsal surface of tongue	C01	Malignant neoplasm of base of tongue
141.2	Malignant neoplasm of tip and lateral border of tongue	C02.0	Malignant neoplasm of dorsal surface of tongue
141.3	Malignant neoplasm of ventral surface of tongue	C02.1	Malignant neoplasm of border of tongue
141.4	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	C02.2	Malignant neoplasm of ventral surface of tongue
141.5	Malignant neoplasm of junctional zone of tongue	C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
141.6	Malignant neoplasm of lingual tonsil	C02.4	Malignant neoplasm of lingual tonsil
141.8	Malignant neoplasm of other sites of tongue	C02.8	Malignant neoplasm of overlapping sites of tongue
141.9	Malignant neoplasm of tongue, unspecified	C02.9	Malignant neoplasm of tongue, unspecified
142.0	Malignant neoplasm of parotid gland	C03.0	Malignant neoplasm of upper gum
142.1	Malignant neoplasm of submandibular gland	C03.1	Malignant neoplasm of lower gum
142.2	Malignant neoplasm of sublingual gland	C03.9	Malignant neoplasm of gum, unspecified
142.8	Malignant neoplasm of other major salivary glands	C04.0	Malignant neoplasm of anterior floor of mouth
142.9	Malignant neoplasm of salivary gland, unspecified	C04.1	Malignant neoplasm of lateral floor of mouth
143.0	Malignant neoplasm of upper gum	C04.8	Malignant neoplasm of overlapping sites of floor of mouth
143.1	Malignant neoplasm of lower gum	C04.9	Malignant neoplasm of floor of mouth, unspecified
143.8	Malignant neoplasm of other sites of gum	C05.0	Malignant neoplasm of hard palate
143.9	Malignant neoplasm of gum, unspecified	C05.1	Malignant neoplasm of soft palate
144.0	Malignant neoplasm of anterior portion of floor of mouth	C05.2	Malignant neoplasm of uvula
144.1	Malignant neoplasm of lateral portion of floor of mouth	C05.8	Malignant neoplasm of overlapping sites of palate
144.8	Malignant neoplasm of other sites of floor of mouth	C05.9	Malignant neoplasm of palate, unspecified
144.9	Malignant neoplasm of floor of mouth, part unspecified	C06.0	Malignant neoplasm of cheek mucosa
145.0	Malignant neoplasm of cheek mucosa	C06.1	Malignant neoplasm of vestibule of mouth
145.1	Malignant neoplasm of vestibule of mouth	C06.2	Malignant neoplasm of retromolar area
145.2	Malignant neoplasm of hard palate	C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
145.3	Malignant neoplasm of soft palate	C06.89	Malignant neoplasm of overlapping sites of other parts of mouth
145.4	Malignant neoplasm of uvula	C06.9	Malignant neoplasm of mouth, unspecified
145.5	Malignant neoplasm of palate, unspecified	C07	Malignant neoplasm of parotid gland
145.6	Malignant neoplasm of retromolar area	C08.0	Malignant neoplasm of submandibular gland
145.8	Malignant neoplasm of other specified parts of mouth	C08.1	Malignant neoplasm of sublingual gland
145.9	Malignant neoplasm of mouth, unspecified	C08.9	Malignant neoplasm of major salivary gland, unspecified
146.0	Malignant neoplasm of tonsil	C09.0	Malignant neoplasm of tonsillar fossa
146.1	Malignant neoplasm of tonsillar fossa	C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
146.2	Malignant neoplasm of tonsillar pillars (anterior) (posterior)	C09.8	Malignant neoplasm of overlapping sites of tonsil
146.3	Malignant neoplasm of vallecula	C09.9	Malignant neoplasm of tonsil, unspecified
146.4	Malignant neoplasm of anterior aspect of epiglottis	C10.0	Malignant neoplasm of vallecula
146.5	Malignant neoplasm of junctional region of oropharynx	C10.1	Malignant neoplasm of anterior surface of epiglottis
146.6	Malignant neoplasm of lateral wall of oropharynx	C10.2	Malignant neoplasm of lateral wall of oropharynx
146.7	Malignant neoplasm of posterior wall of oropharynx	C10.3	Malignant neoplasm of posterior wall of oropharynx
146.8	Malignant neoplasm of other specified sites of oropharynx	C10.4	Malignant neoplasm of branchial cleft
146.9	Malignant neoplasm of oropharynx, unspecified	C10.8	Malignant neoplasm of overlapping sites of oropharynx
147.0	Malignant neoplasm of superior wall of nasopharynx	C10.9	Malignant neoplasm of oropharynx, unspecified
147.1	Malignant neoplasm of posterior wall of nasopharynx	C11.0	Malignant neoplasm of superior wall of nasopharynx
147.2	Malignant neoplasm of lateral wall of nasopharynx	C11.1	Malignant neoplasm of posterior wall of nasopharynx
147.3	Malignant neoplasm of anterior wall of nasopharynx	C11.2	Malignant neoplasm of lateral wall of nasopharynx
147.8	Malignant neoplasm of other specified sites of nasopharynx	C11.3	Malignant neoplasm of anterior wall of nasopharynx
147.9	Malignant neoplasm of nasopharynx, unspecified	C11.8	Malignant neoplasm of overlapping sites of nasopharynx
148.0	Malignant neoplasm of postcricoid region of hypopharynx	C11.9	Malignant neoplasm of nasopharynx, unspecified
148.1	Malignant neoplasm of pyriform sinus	C12	Malignant neoplasm of pyriform sinus
148.2	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	C13.0	Malignant neoplasm of postcricoid region
148.3	Malignant neoplasm of posterior hypopharyngeal wall	C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
148.8	Malignant neoplasm of other specified sites of hypopharynx	C13.2	Malignant neoplasm of posterior wall of hypopharynx
148.9	Malignant neoplasm of hypopharynx, unspecified	C13.8	Malignant neoplasm of overlapping sites of hypopharynx
149.0	Malignant neoplasm of pharynx, unspecified	C13.9	Malignant neoplasm of hypopharynx, unspecified
149.1	Malignant neoplasm of Waldeyer's ring	C14.0	Malignant neoplasm of pharynx, unspecified
149.8	Malignant neoplasm of other sites within the lip and oral cavity	C14.2	Malignant neoplasm of Waldeyer's ring
149.9	Malignant neoplasm of ill-defined sites within the lip and oral cavity	C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
150.0	Malignant neoplasm of cervical esophagus	C15.3	Malignant neoplasm of upper third of esophagus
150.1	Malignant neoplasm of thoracic esophagus	C15.4	Malignant neoplasm of middle third of esophagus
150.2	Malignant neoplasm of abdominal esophagus	C15.5	Malignant neoplasm of lower third of esophagus
150.3	Malignant neoplasm of upper third of esophagus	C15.8	Malignant neoplasm of overlapping sites of esophagus
150.4	Malignant neoplasm of middle third of esophagus	C15.9	Malignant neoplasm of esophagus, unspecified
150.5	Malignant neoplasm of lower third of esophagus	C16.0	Malignant neoplasm of cardia
150.8	Malignant neoplasm of other specified part of esophagus	C16.1	Malignant neoplasm of fundus of stomach
150.9	Malignant neoplasm of esophagus, unspecified	C16.2	Malignant neoplasm of body of stomach
151.0	Malignant neoplasm of cardia	C16.3	Malignant neoplasm of pyloric antrum
151.1	Malignant neoplasm of pylorus	C16.4	Malignant neoplasm of pylorus
151.2	Malignant neoplasm of pyloric antrum	C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
151.3	Malignant neoplasm of fundus of stomach	C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
151.4	Malignant neoplasm of body of stomach	C16.8	Malignant neoplasm of overlapping sites of stomach
151.5	Malignant neoplasm of lesser curvature of stomach, unspecified	C16.9	Malignant neoplasm of stomach, unspecified
151.6	Malignant neoplasm of greater curvature of stomach, unspecified	C17.0	Malignant neoplasm of duodenum
151.8	Malignant neoplasm of other specified sites of stomach	C17.1	Malignant neoplasm of jejunum
151.9	Malignant neoplasm of stomach, unspecified	C17.2	Malignant neoplasm of ileum
152.0	Malignant neoplasm of duodenum	C17.3	Meckel's diverticulum
152.1	Malignant neoplasm of jejunum	C17.8	Malignant neoplasm of overlapping sites of small intestine
152.2	Malignant neoplasm of ileum	C17.9	Malignant neoplasm of small intestine, unspecified

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
152.3	Malignant neoplasm of meckel's diverticulum	C18.0	Malignant neoplasm of cecum
152.8	Malignant neoplasm of other specified sites of small intestine	C18.1	Malignant neoplasm of appendix
152.9	Malignant neoplasm of small intestine, unspecified	C18.2	Malignant neoplasm of ascending colon
153.0	Malignant neoplasm of hepatic flexure	C18.3	Malignant neoplasm of hepatic flexure
153.1	Malignant neoplasm of transverse colon	C18.4	Malignant neoplasm of transverse colon
153.2	Malignant neoplasm of descending colon	C18.5	Malignant neoplasm of splenic flexure
153.3	Malignant neoplasm of sigmoid colon	C18.6	Malignant neoplasm of descending colon
153.4	Malignant neoplasm of cecum	C18.7	Malignant neoplasm of sigmoid colon
153.5	Malignant neoplasm of appendix vermiformis	C18.8	Malignant neoplasm of overlapping sites of colon
153.6	Malignant neoplasm of ascending colon	C18.9	Malignant neoplasm of colon, unspecified
153.7	Malignant neoplasm of splenic flexure	C19	Malignant neoplasm of rectosigmoid junction
153.8	Malignant neoplasm of other specified sites of large intestine	C20	Malignant neoplasm of rectum
153.9	Malignant neoplasm of colon, unspecified	C21.0	Malignant neoplasm of anus, unspecified
154.0	Malignant neoplasm of rectosigmoid junction	C21.1	Malignant neoplasm of anal canal
154.1	Malignant neoplasm of rectum	C21.2	Malignant neoplasm of cloacogenic zone
154.2	Malignant neoplasm of anal canal	C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
154.3	Malignant neoplasm of anus, unspecified	C22.0	Liver cell carcinoma
154.8	Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus	C22.1	Intrahepatic bile duct carcinoma
155.0	Malignant neoplasm of liver, primary	C22.2	Hepatoblastoma
155.1	Malignant neoplasm of intrahepatic bile ducts	C22.3	Angiosarcoma of liver
155.2	Malignant neoplasm of liver, not specified as primary or secondary	C22.4	Other sarcomas of liver
156.0	Malignant neoplasm of gallbladder	C22.7	Other specified carcinomas of liver
156.1	Malignant neoplasm of extrahepatic bile ducts	C22.8	Malignant neoplasm of liver, primary, unspecified as to type
156.2	Malignant neoplasm of ampulla of Vater	C22.9	Malignant neoplasm of liver, not specified as primary or secondary
156.8	Malignant neoplasm of other specified sites of gallbladder and extrahepatic bile ducts	C23	Malignant neoplasm of gallbladder
156.9	Malignant neoplasm of biliary tract, part unspecified	C24.0	Malignant neoplasm of extrahepatic bile duct
157.0	Malignant neoplasm of head of pancreas	C24.1	Malignant neoplasm of ampulla of Vater
157.1	Malignant neoplasm of body of pancreas	C24.8	Malignant neoplasm of overlapping sites of biliary tract
157.2	Malignant neoplasm of tail of pancreas	C24.9	Malignant neoplasm of biliary tract, unspecified
157.3	Malignant neoplasm of pancreatic duct	C25.0	Malignant neoplasm of head of pancreas
157.4	Malignant neoplasm of islets of Langerhans	C25.1	Malignant neoplasm of body of pancreas
157.8	Malignant neoplasm of other specified sites of pancreas	C25.2	Malignant neoplasm of tail of pancreas
157.9	Malignant neoplasm of pancreas, part unspecified	C25.3	Malignant neoplasm of pancreatic duct
158.0	Malignant neoplasm of retroperitoneum	C25.4	Malignant neoplasm of endocrine pancreas
158.8	Malignant neoplasm of specified parts of peritoneum	C25.7	Malignant neoplasm of other parts of pancreas
158.9	Malignant neoplasm of peritoneum, unspecified	C25.8	Malignant neoplasm of overlapping sites of pancreas
159.0	Malignant neoplasm of intestinal tract, part unspecified	C25.9	Malignant neoplasm of pancreas, unspecified
159.1	Malignant neoplasm of spleen, not elsewhere classified	C26.0	Malignant neoplasm of intestinal tract, part unspecified
159.8	Malignant neoplasm of other sites of digestive system and intra-abdominal organs	C26.1	Malignant neoplasm of spleen
159.9	Malignant neoplasm of ill-defined sites within the digestive organs and peritoneum	C26.9	Malignant neoplasm of ill-defined sites within the digestive system
160.0	Malignant neoplasm of nasal cavities	C30.0	Malignant neoplasm of nasal cavity
160.1	Malignant neoplasm of auditory tube, middle ear, and mastoid air cells	C30.1	Malignant neoplasm of middle ear
160.2	Malignant neoplasm of maxillary sinus	C31.0	Malignant neoplasm of maxillary sinus
160.3	Malignant neoplasm of ethmoidal sinus	C31.1	Malignant neoplasm of ethmoidal sinus
160.4	Malignant neoplasm of frontal sinus	C31.2	Malignant neoplasm of frontal sinus
160.5	Malignant neoplasm of sphenoidal sinus	C31.3	Malignant neoplasm of sphenoid sinus
160.8	Malignant neoplasm of other accessory sinuses	C31.8	Malignant neoplasm of overlapping sites of accessory sinuses
160.9	Malignant neoplasm of accessory sinus, unspecified	C31.9	Malignant neoplasm of accessory sinus, unspecified
161.0	Malignant neoplasm of glottis	C32.0	Malignant neoplasm of glottis
161.1	Malignant neoplasm of supraglottis	C32.1	Malignant neoplasm of supraglottis
161.2	Malignant neoplasm of subglottis	C32.2	Malignant neoplasm of subglottis
161.3	Malignant neoplasm of laryngeal cartilages	C32.3	Malignant neoplasm of laryngeal cartilage
161.8	Malignant neoplasm of other specified sites of larynx	C32.8	Malignant neoplasm of overlapping sites of larynx
161.9	Malignant neoplasm of larynx, unspecified	C32.9	Malignant neoplasm of larynx, unspecified
162.0	Malignant neoplasm of trachea	C33	Malignant neoplasm of trachea
162.2	Malignant neoplasm of main bronchus	C34.00	Malignant neoplasm of main bronchus, unspecified side
162.3	Malignant neoplasm of upper lobe, bronchus or lung	C34.01	Malignant neoplasm of right main bronchus
162.4	Malignant neoplasm of middle lobe, bronchus or lung	C34.02	Malignant neoplasm of left main bronchus
162.5	Malignant neoplasm of lower lobe, bronchus or lung	C34.10	Malignant neoplasm of upper lobe, bronchus or lung, unspecified side
162.8	Malignant neoplasm of other parts of bronchus or lung	C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
162.9	Malignant neoplasm of bronchus and lung, unspecified	C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
163.0	Malignant neoplasm of parietal pleura	C34.2	Malignant neoplasm of middle lobe, right bronchus or lung
163.1	Malignant neoplasm of visceral pleura	C34.30	Malignant neoplasm of lower lobe, bronchus or lung, unspecified side
163.8	Malignant neoplasm of other specified sites of pleura	C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
163.9	Malignant neoplasm of pleura, unspecified	C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
164.0	Malignant neoplasm of thymus	C34.80	Malignant neoplasm of overlapping sites of bronchus and lung, unspecified side
164.1	Malignant neoplasm of heart	C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
164.2	Malignant neoplasm of anterior mediastinum	C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
164.3	Malignant neoplasm of posterior mediastinum	C34.90	Malignant neoplasm of bronchus or lung, unspecified, unspecified side
164.8	Malignant neoplasm of other parts of mediastinum	C34.91	Malignant neoplasm of right bronchus or lung, unspecified
164.9	Malignant neoplasm of mediastinum, part unspecified	C34.92	Malignant neoplasm of left bronchus or lung, unspecified
165.0	Malignant neoplasm of upper respiratory tract, part unspecified	C37	Malignant neoplasm of thymus
165.8	Malignant neoplasm of other sites within the respiratory system and intrathoracic organs	C38.0	Malignant neoplasm of heart
165.9	Malignant neoplasm of ill-defined sites within the respiratory system	C38.1	Malignant neoplasm of anterior mediastinum
170.0	Malignant neoplasm of bones of skull and face, except mandible	C38.2	Malignant neoplasm of posterior mediastinum
170.1	Malignant neoplasm of mandible	C38.3	Malignant neoplasm of mediastinum, part unspecified
170.2	Malignant neoplasm of vertebral column, excluding sacrum and coccyx	C38.4	Malignant neoplasm of pleura
170.3	Malignant neoplasm of ribs, sternum, and clavicle	C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
170.4	Malignant neoplasm of scapula and long bones of upper limb	C39.0	Malignant neoplasm of upper respiratory tract, part unspecified
170.5	Malignant neoplasm of short bones of upper limb	C39.9	Malignant neoplasm of lower respiratory tract, part unspecified
170.6	Malignant neoplasm of pelvic bones, sacrum, and coccyx	C40.00	Malignant neoplasm of scapula and long bones of upper limb, unspecified side
170.7	Malignant neoplasm of long bones of lower limb	C40.01	Malignant neoplasm of scapula and long bones of right upper limb
170.8	Malignant neoplasm of short bones of lower limb	C40.02	Malignant neoplasm of scapula and long bones of left upper limb
170.9	Malignant neoplasm of bone and articular cartilage, site unspecified	C40.10	Malignant neoplasm of short bones of upper limb, unspecified side
171.0	Malignant neoplasm of connective and other soft tissue of head, face, and neck	C40.11	Malignant neoplasm of short bones of right upper limb

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
171.2	Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder	C40.12	Malignant neoplasm of short bones of left upper limb
171.3	Malignant neoplasm of connective and other soft tissue of lower limb, including hip	C40.20	Malignant neoplasm of long bones of lower limb, unspecified side
171.4	Malignant neoplasm of connective and other soft tissue of thorax	C40.21	Malignant neoplasm of long bones of right lower limb
171.5	Malignant neoplasm of connective and other soft tissue of abdomen	C40.22	Malignant neoplasm of long bones of left lower limb
171.6	Malignant neoplasm of connective and other soft tissue of pelvis	C40.30	Malignant neoplasm of short bones of lower limb, unspecified side
171.7	Malignant neoplasm of connective and other soft tissue of trunk, unspecified	C40.31	Malignant neoplasm of short bones of right lower limb
171.8	Malignant neoplasm of other specified sites of connective and other soft tissue	C40.32	Malignant neoplasm of short bones of left lower limb
171.9	Malignant neoplasm of connective and other soft tissue, site unspecified	C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of limb, unspecified side
172.0	Malignant melanoma of skin of lip	C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb
172.1	Malignant melanoma of skin of eyelid, including canthus	C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb
172.2	Malignant melanoma of skin of ear and external auditory canal	C40.90	Malignant neoplasm of bones and articular cartilage of limb, unspecified, unspecified side
172.3	Malignant melanoma of skin of other and unspecified parts of face	C40.91	Malignant neoplasm of bones and articular cartilage of right limb, unspecified
172.4	Malignant melanoma of skin of scalp and neck	C40.92	Malignant neoplasm of bones and articular cartilage of left limb, unspecified
172.5	Malignant melanoma of skin of trunk, except scrotum	C41.0	Malignant neoplasm of bones of skull and face
172.6	Malignant melanoma of skin of upper limb, including shoulder	C41.1	Malignant neoplasm of mandible
172.7	Malignant melanoma of skin of lower limb, including hip	C41.2	Malignant neoplasm of vertebral column
172.8	Malignant melanoma of other specified sites of skin	C41.3	Malignant neoplasm of ribs, sternum and clavicle
172.9	Melanoma of skin, site unspecified	C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx
173.00	Unspecified malignant neoplasm of skin of lip	C41.9	Malignant neoplasm of bone and articular cartilage, unspecified
173.01	Basal cell carcinoma of skin of lip	C43.0	Malignant melanoma of lip
173.02	Squamous cell carcinoma of skin of lip	C43.10	Malignant melanoma of eyelid, including canthus, unspecified side
173.09	Other specified malignant neoplasm of skin of lip	C43.11	Malignant melanoma of right eyelid, including canthus
173.10	Unspecified malignant neoplasm of eyelid, including canthus	C43.12	Malignant melanoma of left eyelid, including canthus
173.11	Basal cell carcinoma of eyelid, including canthus	C43.20	Malignant melanoma of ear and external auricular canal, unspecified side
173.12	Squamous cell carcinoma of eyelid, including canthus	C43.21	Malignant melanoma of right ear and external auricular canal
173.19	Other specified malignant neoplasm of eyelid, including canthus	C43.22	Malignant melanoma of left ear and external auricular canal
173.20	Unspecified malignant neoplasm of skin of ear and external auditory canal	C43.30	Malignant melanoma of unspecified part of face
173.21	Basal cell carcinoma of skin of ear and external auditory canal	C43.31	Malignant melanoma of nose
173.22	Squamous cell carcinoma of skin of ear and external auditory canal	C43.39	Malignant melanoma of other parts of face
173.29	Other specified malignant neoplasm of skin of ear and external auditory canal	C43.4	Malignant melanoma of scalp and neck
173.30	Unspecified malignant neoplasm of skin of other and unspecified parts of face	C43.51	Malignant melanoma of anal skin
173.31	Basal cell carcinoma of skin of other and unspecified parts of face	C43.52	Malignant melanoma of skin of breast
173.32	Squamous cell carcinoma of skin of other and unspecified parts of face	C43.59	Malignant melanoma of other part of trunk
173.39	Other specified malignant neoplasm of skin of other and unspecified parts of face	C43.60	Malignant melanoma of upper limb, including shoulder, unspecified side
173.40	Unspecified malignant neoplasm of scalp and skin of neck	C43.61	Malignant melanoma of right upper limb, including shoulder
173.41	Basal cell carcinoma of scalp and skin of neck	C43.62	Malignant melanoma of left upper limb, including shoulder
173.42	Squamous cell carcinoma of scalp and skin of neck	C43.70	Malignant melanoma of lower limb, including hip, unspecified side
173.49	Other specified malignant neoplasm of scalp and skin of neck	C43.71	Malignant melanoma of right lower limb, including hip
173.50	Unspecified malignant neoplasm of skin of trunk, except scrotum	C43.72	Malignant melanoma of left lower limb, including hip
173.51	Basal cell carcinoma of skin of trunk, except scrotum	C43.8	Overlapping malignant melanoma of skin
173.52	Squamous cell carcinoma of skin of trunk, except scrotum	C43.9	Malignant melanoma of skin, unspecified
173.59	Other specified malignant neoplasm of skin of trunk, except scrotum	C44.0	Malignant neoplasm of skin of lip
173.60	Unspecified malignant neoplasm of skin of upper limb, including shoulder	C44.10	Malignant neoplasm of skin of eyelid, including canthus, unspecified side
173.61	Basal cell carcinoma of skin of upper limb, including shoulder	C44.11	Malignant neoplasm of skin of right eyelid, including canthus
173.62	Squamous cell carcinoma of skin of upper limb, including shoulder	C44.12	Malignant neoplasm of skin of left eyelid, including canthus
173.69	Other specified malignant neoplasm of skin of upper limb, including shoulder	C44.20	Malignant neoplasm of skin of ear and external auricular canal, unspecified side
173.70	Unspecified malignant neoplasm of skin of lower limb, including hip	C44.21	Malignant neoplasm of skin of right ear and external auricular canal
173.71	Basal cell carcinoma of skin of lower limb, including hip	C44.22	Malignant neoplasm of skin of left ear and external auricular canal
173.72	Squamous cell carcinoma of skin of lower limb, including hip	C44.30	Malignant neoplasm of skin of unspecified part of face
173.79	Other specified malignant neoplasm of skin of lower limb, including hip	C44.31	Malignant neoplasm of skin of nose
173.80	Unspecified malignant neoplasm of other specified sites of skin	C44.39	Malignant neoplasm of skin of other parts of face
173.81	Basal cell carcinoma of other specified sites of skin	C44.4	Malignant neoplasm of skin of scalp and neck
173.82	Squamous cell carcinoma of other specified sites of skin	C44.51	Malignant neoplasm of anal skin
173.89	Other specified malignant neoplasm of other specified sites of skin	C44.52	Malignant neoplasm of skin of breast
173.90	Unspecified malignant neoplasm of skin, site unspecified	C44.59	Malignant neoplasm of other part of trunk
173.91	Basal cell carcinoma of skin, site unspecified	C44.60	Malignant neoplasm of skin of upper limb, including shoulder, unspecified side
173.92	Squamous cell carcinoma of skin, site unspecified	C44.61	Malignant neoplasm of skin of right upper limb, including shoulder
173.99	Other specified malignant neoplasm of skin, site unspecified	C44.62	Malignant neoplasm of skin of left upper limb, including shoulder
174.0	Malignant neoplasm of nipple and areola of female breast	C44.70	Malignant neoplasm of skin of lower limb, including hip, unspecified side
174.1	Malignant neoplasm of central portion of female breast	C44.71	Malignant neoplasm of skin of right lower limb, including hip
174.2	Malignant neoplasm of upper-inner quadrant of female breast	C44.72	Malignant neoplasm of skin of left lower limb, including hip
174.3	Malignant neoplasm of lower-inner quadrant of female breast	C44.8	Malignant neoplasm of overlapping sites of skin
174.4	Malignant neoplasm of upper-outer quadrant of female breast	C44.9	Malignant neoplasm of skin, unspecified
174.5	Malignant neoplasm of lower-outer quadrant of female breast	C45.0	Mesothelioma of pleura
174.6	Malignant neoplasm of axillary tail of female breast	C45.1	Mesothelioma of peritoneum
174.8	Malignant neoplasm of other specified sites of female breast	C45.2	Mesothelioma of pericardium
174.9	Malignant neoplasm of breast (female), unspecified	C45.7	Mesothelioma of other sites
175.0	Malignant neoplasm of nipple and areola of male breast	C45.9	Mesothelioma, unspecified
175.9	Malignant neoplasm of other and unspecified sites of male breast	C46.0	Kaposi's sarcoma of skin
176.0	Kaposi's sarcoma, skin	C46.1	Kaposi's sarcoma of soft tissue
176.1	Kaposi's sarcoma, soft tissue	C46.2	Kaposi's sarcoma of palate
176.2	Kaposi's sarcoma, palate	C46.3	Kaposi's sarcoma of lymph nodes
176.3	Kaposi's sarcoma, gastrointestinal sites	C46.4	Kaposi's sarcoma of gastrointestinal sites
176.4	Kaposi's sarcoma, lung	C46.50	Kaposi's sarcoma of lung, unspecified side
176.5	Kaposi's sarcoma, lymph nodes	C46.51	Kaposi's sarcoma of right lung
176.8	Kaposi's sarcoma, other specified sites	C46.52	Kaposi's sarcoma of left lung
176.9	Kaposi's sarcoma, unspecified	C46.7	Kaposi's sarcoma of other sites
179	Malignant neoplasm of uterus, part unspecified	C46.9	Kaposi's sarcoma, unspecified
180.0	Malignant neoplasm of endocervix	C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
180.1	Malignant neoplasm of exocervix	C47.10	Malignant neoplasm of peripheral nerves of upper limb, including shoulder, unspecified side
180.8	Malignant neoplasm of other specified sites of cervix	C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
180.9	Malignant neoplasm of cervix uteri, unspecified	C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
181	Malignant neoplasm of placenta	C47.20	Malignant neoplasm of peripheral nerves of lower limb, including hip, unspecified side
182.0	Malignant neoplasm of corpus uteri, except isthmus	C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
182.1	Malignant neoplasm of isthmus	C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip
182.8	Malignant neoplasm of other specified sites of body of uterus	C47.3	Malignant neoplasm of peripheral nerves of thorax
183.0	Malignant neoplasm of ovary	C47.4	Malignant neoplasm of peripheral nerves of abdomen
183.2	Malignant neoplasm of fallopian tube	C47.5	Malignant neoplasm of peripheral nerves of pelvis
183.3	Malignant neoplasm of broad ligament of uterus	C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
183.4	Malignant neoplasm of parametrium	C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
183.5	Malignant neoplasm of round ligament of uterus	C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
183.8	Malignant neoplasm of other specified sites of uterine adnexa	C48.0	Malignant neoplasm of retroperitoneum
183.9	Malignant neoplasm of uterine adnexa, unspecified	C48.1	Malignant neoplasm of specified parts of peritoneum
184.0	Malignant neoplasm of vagina	C48.2	Malignant neoplasm of peritoneum, unspecified
184.1	Malignant neoplasm of labia majora	C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
184.2	Malignant neoplasm of labia minora	C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
184.3	Malignant neoplasm of clitoris	C49.10	Malignant neoplasm of connective and soft tissue of upper limb, including shoulder, unspecified side
184.4	Malignant neoplasm of vulva, unspecified	C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
184.8	Malignant neoplasm of other specified sites of female genital organs	C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
184.9	Malignant neoplasm of female genital organ, site unspecified	C49.20	Malignant neoplasm of connective and soft tissue of lower limb, including hip, unspecified side
185	Malignant neoplasm of prostate	C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
186.0	Malignant neoplasm of undescended testis	C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
186.9	Malignant neoplasm of other and unspecified testis	C49.3	Malignant neoplasm of connective and soft tissue of thorax
187.1	Malignant neoplasm of prepuce	C49.4	Malignant neoplasm of connective and soft tissue of abdomen
187.2	Malignant neoplasm of glans penis	C49.5	Malignant neoplasm of connective and soft tissue of pelvis
187.3	Malignant neoplasm of body of penis	C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
187.4	Malignant neoplasm of penis, part unspecified	C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
187.5	Malignant neoplasm of epididymis	C49.9	Malignant neoplasm of connective and soft tissue, unspecified
187.6	Malignant neoplasm of spermatic cord	C4A.0	Merkel cell carcinoma of lip
187.7	Malignant neoplasm of scrotum	C4A.10	Merkel cell carcinoma of eyelid, including canthus, unspecified side
187.8	Malignant neoplasm of other specified sites of male genital organs	C4A.11	Merkel cell carcinoma of right eyelid, including canthus
187.9	Malignant neoplasm of male genital organ, site unspecified	C4A.12	Merkel cell carcinoma of left eyelid, including canthus
188.0	Malignant neoplasm of trigone of urinary bladder	C4A.20	Merkel cell carcinoma of ear and external auricular canal, unspecified side
188.1	Malignant neoplasm of dome of urinary bladder	C4A.21	Merkel cell carcinoma of right ear and external auricular canal
188.2	Malignant neoplasm of lateral wall of urinary bladder	C4A.22	Merkel cell carcinoma of left ear and external auricular canal
188.3	Malignant neoplasm of anterior wall of urinary bladder	C4A.30	Merkel cell carcinoma of unspecified part of face
188.4	Malignant neoplasm of posterior wall of urinary bladder	C4A.31	Merkel cell carcinoma of nose
188.5	Malignant neoplasm of bladder neck	C4A.39	Merkel cell carcinoma of other parts of face
188.6	Malignant neoplasm of ureteric orifice	C4A.4	Merkel cell carcinoma of scalp and neck
188.7	Malignant neoplasm of urachus	C4A.51	Merkel cell carcinoma of anal skin
188.8	Malignant neoplasm of other specified sites of bladder	C4A.52	Merkel cell carcinoma of skin of breast
188.9	Malignant neoplasm of bladder, part unspecified	C4A.59	Merkel cell carcinoma of other part of trunk
189.0	Malignant neoplasm of kidney, except pelvis	C4A.60	Merkel cell carcinoma of upper limb, including shoulder, unspecified side
189.1	Malignant neoplasm of renal pelvis	C4A.61	Merkel cell carcinoma of right upper limb, including shoulder
189.2	Malignant neoplasm of ureter	C4A.62	Merkel cell carcinoma of left upper limb, including shoulder
189.3	Malignant neoplasm of urethra	C4A.70	Merkel cell carcinoma of lower limb, including hip, unspecified side
189.4	Malignant neoplasm of paraurethral glands	C4A.71	Merkel cell carcinoma of right lower limb, including hip
189.8	Malignant neoplasm of other specified sites of urinary organs	C4A.72	Merkel cell carcinoma of left lower limb, including hip
189.9	Malignant neoplasm of urinary organ, site unspecified	C4A.8	Merkel cell carcinoma of overlapping sites
190.0	Malignant neoplasm of eyeball, except conjunctiva, cornea, retina, and choroid	C4A.9	Merkel cell carcinoma, unspecified
190.1	Malignant neoplasm of orbit	C50.011	Malignant neoplasm of nipple and areola, right female breast
190.2	Malignant neoplasm of lacrimal gland	C50.012	Malignant neoplasm of nipple and areola, left female breast
190.3	Malignant neoplasm of conjunctiva	C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
190.4	Malignant neoplasm of cornea	C50.021	Malignant neoplasm of nipple and areola, right male breast
190.5	Malignant neoplasm of retina	C50.022	Malignant neoplasm of nipple and areola, left male breast
190.6	Malignant neoplasm of choroid	C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
190.7	Malignant neoplasm of lacrimal duct	C50.111	Malignant neoplasm of central portion of right female breast
190.8	Malignant neoplasm of other specified sites of eye	C50.112	Malignant neoplasm of central portion of left female breast
190.9	Malignant neoplasm of eye, part unspecified	C50.119	Malignant neoplasm of central portion of unspecified female breast
191.0	Malignant neoplasm of cerebrum, except lobes and ventricles	C50.121	Malignant neoplasm of central portion of right male breast
191.1	Malignant neoplasm of frontal lobe	C50.122	Malignant neoplasm of central portion of left male breast
191.2	Malignant neoplasm of temporal lobe	C50.129	Malignant neoplasm of central portion of unspecified male breast
191.3	Malignant neoplasm of parietal lobe	C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
191.4	Malignant neoplasm of occipital lobe	C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
191.5	Malignant neoplasm of ventricles	C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
191.6	Malignant neoplasm of cerebellum NOS	C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
191.7	Malignant neoplasm of brain stem	C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
191.8	Malignant neoplasm of other parts of brain	C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
191.9	Malignant neoplasm of brain, unspecified	C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
192.0	Malignant neoplasm of cranial nerves	C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
192.1	Malignant neoplasm of cerebral meninges	C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
192.2	Malignant neoplasm of spinal cord	C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
192.3	Malignant neoplasm of spinal meninges	C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
192.8	Malignant neoplasm of other specified sites of nervous system	C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
192.9	Malignant neoplasm of nervous system, part unspecified	C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
193	Malignant neoplasm of thyroid gland	C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
194.0	Malignant neoplasm of adrenal gland	C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
194.1	Malignant neoplasm of parathyroid gland	C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
194.3	Malignant neoplasm of pituitary gland and craniopharyngeal duct	C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
194.4	Malignant neoplasm of pineal gland	C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast
194.5	Malignant neoplasm of carotid body	C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
194.6	Malignant neoplasm of aortic body and other paraganglia	C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
194.8	Malignant neoplasm of other endocrine glands and related structures	C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
194.9	Malignant neoplasm of endocrine gland, site unspecified	C50.521	Malignant neoplasm of lower-outer quadrant of right male breast

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
195.0	Malignant neoplasm of head, face, and neck	C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
195.1	Malignant neoplasm of thorax	C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
195.2	Malignant neoplasm of abdomen	C50.611	Malignant neoplasm of axillary tail of right female breast
195.3	Malignant neoplasm of pelvis	C50.612	Malignant neoplasm of axillary tail of left female breast
195.4	Malignant neoplasm of upper limb	C50.619	Malignant neoplasm of axillary tail of unspecified female breast
195.5	Malignant neoplasm of lower limb	C50.621	Malignant neoplasm of axillary tail of right male breast
195.8	Malignant neoplasm of other specified sites	C50.622	Malignant neoplasm of axillary tail of left male breast
196.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck	C50.629	Malignant neoplasm of axillary tail of unspecified male breast
196.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	C50.811	Malignant neoplasm of overlapping sites of right female breast
196.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	C50.812	Malignant neoplasm of overlapping sites of left female breast
196.3	Secondary and unspecified malignant neoplasm of lymph nodes of axilla and upper limb	C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
196.5	Secondary and unspecified malignant neoplasm of lymph nodes of inguinal region and lower limb	C50.821	Malignant neoplasm of overlapping sites of right male breast
196.6	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	C50.822	Malignant neoplasm of overlapping sites of left male breast
196.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites	C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
196.9	Secondary and unspecified malignant neoplasm of lymph nodes, site unspecified	C50.911	Malignant neoplasm of unspecified site of right female breast
197.0	Secondary malignant neoplasm of lung	C50.912	Malignant neoplasm of unspecified site of left female breast
197.1	Secondary malignant neoplasm of mediastinum	C50.919	Malignant neoplasm of unspecified site of unspecified female breast
197.2	Secondary malignant neoplasm of pleura	C50.921	Malignant neoplasm of unspecified site of left male breast
197.3	Secondary malignant neoplasm of other respiratory organs	C50.922	Malignant neoplasm of unspecified site of left male breast
197.4	Secondary malignant neoplasm of small intestine including duodenum	C50.929	Malignant neoplasm of unspecified site of unspecified male breast
197.5	Secondary malignant neoplasm of large intestine and rectum	C51.0	Malignant neoplasm of labium majus
197.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	C51.1	Malignant neoplasm of labium minus
197.7	Malignant neoplasm of liver, specified as secondary	C51.2	Malignant neoplasm of clitoris
197.8	Secondary malignant neoplasm of other digestive organs and spleen	C51.8	Malignant neoplasm of overlapping sites of vulva
198.0	Secondary malignant neoplasm of kidney	C51.9	Malignant neoplasm of vulva, unspecified
198.1	Secondary malignant neoplasm of other urinary organs	C52	Malignant neoplasm of vagina
198.2	Secondary malignant neoplasm of skin	C53.0	Malignant neoplasm of endocervix
198.3	Secondary malignant neoplasm of brain and spinal cord	C53.1	Malignant neoplasm of exocervix
198.4	Secondary malignant neoplasm of other parts of nervous system	C53.8	Malignant neoplasm of overlapping sites of cervix uteri
198.5	Secondary malignant neoplasm of bone and bone marrow	C53.9	Malignant neoplasm of cervix uteri, unspecified
198.6	Secondary malignant neoplasm of ovary	C54.0	Malignant neoplasm of isthmus uteri
198.7	Secondary malignant neoplasm of adrenal gland	C54.1	Malignant neoplasm of endometrium
198.81	Secondary malignant neoplasm of breast	C54.2	Malignant neoplasm of myometrium
198.82	Secondary malignant neoplasm of genital organs	C54.3	Malignant neoplasm of fundus uteri
198.89	Secondary malignant neoplasm of other specified sites	C54.8	Malignant neoplasm of overlapping sites of corpus uteri
199.0	Disseminated malignant neoplasm	C54.9	Malignant neoplasm of corpus uteri, unspecified
199.1	Other malignant neoplasm of unspecified site	C55	Malignant neoplasm of uterus, part unspecified
199.2	Malignant neoplasm associated with transplanted organ	C56.0	Malignant neoplasm of right ovary
200.00	Reticulosarcoma, unspecified site, extranodal and solid organ sites	C56.1	Malignant neoplasm of left ovary
200.01	Reticulosarcoma involving lymph nodes of head, face, and neck	C56.9	Malignant neoplasm of ovary, unspecified side
200.02	Reticulosarcoma involving intrathoracic lymph nodes	C57.00	Malignant neoplasm of fallopian tube, unspecified side
200.03	Reticulosarcoma involving intra-abdominal lymph nodes	C57.01	Malignant neoplasm of right fallopian tube
200.04	Reticulosarcoma involving lymph nodes of axilla and upper limb	C57.02	Malignant neoplasm of left fallopian tube
200.05	Reticulosarcoma involving lymph nodes of inguinal region and lower limb	C57.10	Malignant neoplasm of broad ligament, unspecified side
200.06	Reticulosarcoma involving intrapelvic lymph nodes	C57.11	Malignant neoplasm of right broad ligament
200.07	Reticulosarcoma involving spleen	C57.12	Malignant neoplasm of left broad ligament
200.08	Reticulosarcoma involving lymph nodes of multiple sites	C57.20	Malignant neoplasm of round ligament, unspecified side
200.10	Lymphosarcoma, unspecified site, extranodal and solid organ sites	C57.21	Malignant neoplasm of right round ligament
200.11	Lymphosarcoma involving lymph nodes of head, face, and neck	C57.22	Malignant neoplasm of left round ligament
200.12	Lymphosarcoma involving intrathoracic lymph nodes	C57.3	Malignant neoplasm of parametrium
200.13	Lymphosarcoma involving intra-abdominal lymph nodes	C57.4	Malignant neoplasm of uterine adnexa, unspecified
200.14	Lymphosarcoma involving lymph nodes of axilla and upper limb	C57.7	Malignant neoplasm of other specified female genital organs
200.15	Lymphosarcoma involving lymph nodes of inguinal region and lower limb	C57.8	Malignant neoplasm of overlapping sites of female genital organs
200.16	Lymphosarcoma involving intrapelvic lymph nodes	C57.9	Malignant neoplasm of female genital organ, unspecified
200.17	Lymphosarcoma involving spleen	C58	Malignant neoplasm of placenta
200.18	Lymphosarcoma involving lymph nodes of multiple sites	C60.0	Malignant neoplasm of prepuce
200.20	Burkitt's tumor or lymphoma, unspecified site, extranodal and solid organ sites	C60.1	Malignant neoplasm of glans penis
200.21	Burkitt's tumor or lymphoma involving lymph nodes of head, face, and neck	C60.2	Malignant neoplasm of body of penis
200.22	Burkitt's tumor or lymphoma involving intrathoracic lymph nodes	C60.8	Malignant neoplasm of overlapping sites of penis
200.23	Burkitt's tumor or lymphoma involving intra-abdominal lymph nodes	C60.9	Malignant neoplasm of penis, unspecified
200.24	Burkitt's tumor or lymphoma involving lymph nodes of axilla and upper limb	C61	Malignant neoplasm of prostate
200.25	Burkitt's tumor or lymphoma involving lymph nodes of inguinal region and lower limb	C62.00	Malignant neoplasm of undescended testis, unspecified side
200.26	Burkitt's tumor or lymphoma involving intrapelvic lymph nodes	C62.01	Malignant neoplasm of undescended right testis
200.27	Burkitt's tumor or lymphoma involving spleen	C62.02	Malignant neoplasm of undescended left testis
200.28	Burkitt's tumor or lymphoma involving lymph nodes of multiple sites	C62.10	Malignant neoplasm of descended testis, unspecified side
200.30	Marginal zone lymphoma, unspecified site, extranodal and solid organ sites	C62.11	Malignant neoplasm of descended right testis
200.31	Marginal zone lymphoma involving lymph nodes of head, face, and neck	C62.12	Malignant neoplasm of descended left testis
200.32	Marginal zone lymphoma involving intrathoracic lymph nodes	C62.90	Malignant neoplasm of testis, unspecified, unspecified side
200.33	Marginal zone lymphoma involving intra-abdominal lymph nodes	C62.91	Malignant neoplasm of right testis, unspecified
200.34	Marginal zone lymphoma involving lymph nodes of axilla and upper limb	C62.92	Malignant neoplasm of left testis, unspecified
200.35	Marginal zone lymphoma involving lymph nodes of inguinal region and lower limb	C63.00	Malignant neoplasm of epididymis, unspecified side
200.36	Marginal zone lymphoma involving intrapelvic lymph nodes	C63.01	Malignant neoplasm of right epididymis
200.37	Marginal zone lymphoma involving spleen	C63.02	Malignant neoplasm of left epididymis
200.38	Marginal zone lymphoma involving lymph nodes of multiple sites	C63.10	Malignant neoplasm of spermatic cord, unspecified side
200.40	Mantle cell lymphoma, unspecified site, extranodal and solid organ sites	C63.11	Malignant neoplasm of right spermatic cord
200.41	Mantle cell lymphoma involving lymph nodes of head, face, and neck	C63.12	Malignant neoplasm of left spermatic cord
200.42	Mantle cell lymphoma involving intrathoracic lymph nodes	C63.2	Malignant neoplasm of scrotum
200.43	Mantle cell lymphoma involving intra-abdominal lymph nodes	C63.7	Malignant neoplasm of other specified male genital organs
200.44	Mantle cell lymphoma involving lymph nodes of axilla and upper limb	C63.8	Malignant neoplasm of overlapping sites of male genital organs
200.45	Mantle cell lymphoma involving lymph nodes of inguinal region and lower limb	C63.9	Malignant neoplasm of male genital organ, unspecified
200.46	Mantle cell lymphoma involving intrapelvic lymph nodes	C64.0	Malignant neoplasm of right kidney, except renal pelvis
200.47	Mantle cell lymphoma involving spleen	C64.1	Malignant neoplasm of left kidney, except renal pelvis
200.48	Mantle cell lymphoma involving lymph nodes of multiple sites	C64.9	Malignant neoplasm of kidney, except renal pelvis, unspecified side

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381**Data Element (Value Set Title): Cancer**

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
200.50	Primary central nervous system lymphoma, unspecified site, extranodal and solid organ sites	C65.0	Malignant neoplasm of right renal pelvis
200.51	Primary central nervous system lymphoma involving lymph nodes of head, face, and neck	C65.1	Malignant neoplasm of left renal pelvis
200.52	Primary central nervous system lymphoma involving intrathoracic lymph nodes	C65.9	Malignant neoplasm of renal pelvis, unspecified side
200.53	Primary central nervous system lymphoma involving intra-abdominal lymph nodes	C66.0	Malignant neoplasm of right ureter
200.54	Primary central nervous system lymphoma involving lymph nodes of axilla and upper limb	C66.1	Malignant neoplasm of left ureter
200.55	Primary central nervous system lymphoma involving lymph nodes of inguinal region and lower limb	C66.9	Malignant neoplasm of ureter, unspecified side
200.56	Primary central nervous system lymphoma involving intrapelvic lymph nodes	C67.0	Malignant neoplasm of trigone of bladder
200.57	Primary central nervous system lymphoma involving spleen	C67.1	Malignant neoplasm of dome of bladder
200.58	Primary central nervous system lymphoma involving lymph nodes of multiple sites	C67.2	Malignant neoplasm of lateral wall of bladder
200.60	Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites	C67.3	Malignant neoplasm of anterior wall of bladder
200.61	Anaplastic large cell lymphoma involving lymph nodes of head, face, and neck	C67.4	Malignant neoplasm of posterior wall of bladder
200.62	Anaplastic large cell lymphoma involving intrathoracic lymph nodes	C67.5	Malignant neoplasm of bladder neck
200.63	Anaplastic large cell lymphoma involving intra-abdominal lymph nodes	C67.6	Malignant neoplasm of ureteric orifice
200.64	Anaplastic large cell lymphoma involving lymph nodes of axilla and upper limb	C67.7	Malignant neoplasm of urachus
200.65	Anaplastic large cell lymphoma involving lymph nodes of inguinal region and lower limb	C67.8	Malignant neoplasm of overlapping sites of bladder
200.66	Anaplastic large cell lymphoma involving intrapelvic lymph nodes	C67.9	Malignant neoplasm of bladder, unspecified
200.67	Anaplastic large cell lymphoma involving spleen	C68.0	Malignant neoplasm of urethra
200.68	Anaplastic large cell lymphoma involving lymph nodes of multiple sites	C68.1	Malignant neoplasm of paraurethral glands
200.70	Large cell lymphoma, unspecified site, extranodal and solid organ sites	C68.8	Malignant neoplasm of overlapping sites of urinary organs
200.71	Large cell lymphoma involving lymph nodes of head, face, and neck	C68.9	Malignant neoplasm of urinary organ, unspecified
200.72	Large cell lymphoma involving intrathoracic lymph nodes	C69.00	Malignant neoplasm of conjunctiva, unspecified side
200.73	Large cell lymphoma involving intra-abdominal lymph nodes	C69.01	Malignant neoplasm of right conjunctiva
200.74	Large cell lymphoma involving lymph nodes of axilla and upper limb	C69.02	Malignant neoplasm of left conjunctiva
200.75	Large cell lymphoma involving lymph nodes of inguinal region and lower limb	C69.10	Malignant neoplasm of cornea, unspecified side
200.76	Large cell lymphoma involving intrapelvic lymph nodes	C69.11	Malignant neoplasm of right cornea
200.77	Large cell lymphoma involving spleen	C69.12	Malignant neoplasm of left cornea
200.78	Large cell lymphoma involving lymph nodes of multiple sites	C69.20	Malignant neoplasm of retina, unspecified side
200.80	Other named variants of lymphosarcoma and reticulosarcoma, unspecified site	C69.21	Malignant neoplasm of right retina
200.81	Other named variants of lymphosarcoma and reticulosarcoma involving lymph nodes of head, face, and neck	C69.22	Malignant neoplasm of left retina
200.82	Other named variants of lymphosarcoma and reticulosarcoma involving intrathoracic lymph nodes	C69.30	Malignant neoplasm of choroid, unspecified side
200.83	Other named variants of lymphosarcoma and reticulosarcoma involving intra-abdominal lymph nodes	C69.31	Malignant neoplasm of right choroid
200.84	Other named variants of lymphosarcoma and reticulosarcoma involving lymph nodes of axilla and upper limb	C69.32	Malignant neoplasm of left choroid
200.85	Other named variants of lymphosarcoma and reticulosarcoma involving lymph nodes of inguinal region and lower limb	C69.40	Malignant neoplasm of ciliary body, unspecified side
200.86	Other named variants of lymphosarcoma and reticulosarcoma involving intrapelvic lymph nodes	C69.41	Malignant neoplasm of right ciliary body
200.87	Other named variants of lymphosarcoma and reticulosarcoma involving spleen	C69.42	Malignant neoplasm of left ciliary body
200.88	Other named variants of lymphosarcoma and reticulosarcoma involving lymph nodes of multiple sites	C69.50	Malignant neoplasm of lacrimal gland and duct, unspecified side
201.00	Hodgkin's paraganuloma, unspecified site, extranodal and solid organ sites	C69.51	Malignant neoplasm of right lacrimal gland and duct
201.01	Hodgkin's paraganuloma involving lymph nodes of head, face, and neck	C69.52	Malignant neoplasm of left lacrimal gland and duct
201.02	Hodgkin's paraganuloma involving intrathoracic lymph nodes	C69.60	Malignant neoplasm of orbit, unspecified side
201.03	Hodgkin's paraganuloma involving intra-abdominal lymph nodes	C69.61	Malignant neoplasm of right orbit
201.04	Hodgkin's paraganuloma involving lymph nodes of axilla and upper limb	C69.62	Malignant neoplasm of left orbit
201.05	Hodgkin's paraganuloma involving lymph nodes of inguinal region and lower limb	C69.80	Malignant neoplasm of overlapping sites of eye and adnexa, unspecified side
201.06	Hodgkin's paraganuloma involving intrapelvic lymph nodes	C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa
201.07	Hodgkin's paraganuloma involving spleen	C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa
201.08	Hodgkin's paraganuloma involving lymph nodes of multiple sites	C69.90	Malignant neoplasm of eye, unspecified, unspecified side
201.10	Hodgkin's granuloma, unspecified site, extranodal and solid organ sites	C69.91	Malignant neoplasm of right eye, unspecified
201.11	Hodgkin's granuloma involving lymph nodes of head, face, and neck	C69.92	Malignant neoplasm of left eye, unspecified
201.12	Hodgkin's granuloma involving intrathoracic lymph nodes	C70.0	Malignant neoplasm of cerebral meninges
201.13	Hodgkin's granuloma involving intra-abdominal lymph nodes	C70.1	Malignant neoplasm of spinal meninges
201.14	Hodgkin's granuloma involving lymph nodes of axilla and upper limb	C70.9	Malignant neoplasm of meninges, unspecified
201.15	Hodgkin's granuloma involving lymph nodes of inguinal region and lower limb	C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
201.16	Hodgkin's granuloma involving intrapelvic lymph nodes	C71.1	Malignant neoplasm of frontal lobe
201.17	Hodgkin's granuloma involving spleen	C71.2	Malignant neoplasm of temporal lobe
201.18	Hodgkin's granuloma involving lymph nodes of multiple sites	C71.3	Malignant neoplasm of parietal lobe
201.20	Hodgkin's sarcoma, unspecified site, extranodal and solid organ sites	C71.4	Malignant neoplasm of occipital lobe
201.21	Hodgkin's sarcoma involving lymph nodes of head, face, and neck	C71.5	Malignant neoplasm of cerebral ventricle
201.22	Hodgkin's sarcoma involving intrathoracic lymph nodes	C71.6	Malignant neoplasm of cerebellum
201.23	Hodgkin's sarcoma involving intra-abdominal lymph nodes	C71.7	Malignant neoplasm of brain stem
201.24	Hodgkin's sarcoma involving lymph nodes of axilla and upper limb	C71.8	Malignant neoplasm of overlapping sites of brain
201.25	Hodgkin's sarcoma involving lymph nodes of inguinal region and lower limb	C71.9	Malignant neoplasm of brain, unspecified
201.26	Hodgkin's sarcoma involving intrapelvic lymph nodes	C72.0	Malignant neoplasm of spinal cord
201.27	Hodgkin's sarcoma involving spleen	C72.1	Malignant neoplasm of cauda equina
201.28	Hodgkin's sarcoma involving lymph nodes of multiple sites	C72.20	Malignant neoplasm of olfactory nerve, unspecified side
201.40	Hodgkin's disease, lymphocytic-histiocytic predominance, unspecified site, extranodal and solid organ sites	C72.21	Malignant neoplasm of right olfactory nerve
201.41	Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of head, face, and neck	C72.22	Malignant neoplasm of left olfactory nerve
201.42	Hodgkin's disease, lymphocytic-histiocytic predominance involving intrathoracic lymph nodes	C72.30	Malignant neoplasm of optic nerve, unspecified side
201.43	Hodgkin's disease, lymphocytic-histiocytic predominance involving intra-abdominal lymph nodes	C72.31	Malignant neoplasm of right optic nerve
201.44	Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of axilla and upper limb	C72.32	Malignant neoplasm of left optic nerve
201.45	Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of inguinal region and lower limb	C72.40	Malignant neoplasm of acoustic nerve, unspecified side
201.46	Hodgkin's disease, lymphocytic-histiocytic predominance involving intrapelvic lymph nodes	C72.41	Malignant neoplasm of right acoustic nerve

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381**Data Element (Value Set Title): Cancer**

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
201.47	Hodgkin's disease, lymphocytic-histiocytic predominance involving spleen	C72.42	Malignant neoplasm of left acoustic nerve
201.48	Hodgkin's disease, lymphocytic-histiocytic predominance involving lymph nodes of multiple sites	C72.50	Malignant neoplasm of unspecified cranial nerve
201.50	Hodgkin's disease, nodular sclerosis, unspecified site, extranodal and solid organ sites	C72.59	Malignant neoplasm of other cranial nerves
201.51	Hodgkin's disease, nodular sclerosis, involving lymph nodes of head, face, and neck	C72.9	Malignant neoplasm of central nervous system, unspecified
201.52	Hodgkin's disease, nodular sclerosis, involving intrathoracic lymph nodes	C73	Malignant neoplasm of thyroid gland
201.53	Hodgkin's disease, nodular sclerosis, involving intra-abdominal lymph nodes	C74.00	Malignant neoplasm of cortex of adrenal gland, unspecified side
201.54	Hodgkin's disease, nodular sclerosis, involving lymph nodes of axilla and upper limb	C74.01	Malignant neoplasm of cortex of right adrenal gland
201.55	Hodgkin's disease, nodular sclerosis, involving lymph nodes of inguinal region and lower limb	C74.02	Malignant neoplasm of cortex of left adrenal gland
201.56	Hodgkin's disease, nodular sclerosis, involving intrapelvic lymph nodes	C74.10	Malignant neoplasm of medulla of adrenal gland, unspecified side
201.57	Hodgkin's disease, nodular sclerosis, involving spleen	C74.11	Malignant neoplasm of medulla of right adrenal gland
201.58	Hodgkin's disease, nodular sclerosis, involving lymph nodes of multiple sites	C74.12	Malignant neoplasm of medulla of left adrenal gland
201.60	Hodgkin's disease, mixed cellularity, unspecified site, extranodal and solid organ sites	C74.90	Malignant neoplasm of adrenal gland, unspecified, unspecified side
201.61	Hodgkin's disease, mixed cellularity, involving lymph nodes of head, face, and neck	C74.91	Malignant neoplasm of right adrenal gland, unspecified
201.62	Hodgkin's disease, mixed cellularity, involving intrathoracic lymph nodes	C74.92	Malignant neoplasm of left adrenal gland, unspecified
201.63	Hodgkin's disease, mixed cellularity, involving intra-abdominal lymph nodes	C75.0	Malignant neoplasm of parathyroid gland
201.64	Hodgkin's disease, mixed cellularity, involving lymph nodes of axilla and upper limb	C75.1	Malignant neoplasm of pituitary gland
201.65	Hodgkin's disease, mixed cellularity, involving lymph nodes of inguinal region and lower limb	C75.2	Malignant neoplasm of craniopharyngeal duct
201.66	Hodgkin's disease, mixed cellularity, involving intrapelvic lymph nodes	C75.3	Malignant neoplasm of pineal gland
201.67	Hodgkin's disease, mixed cellularity, involving spleen	C75.4	Malignant neoplasm of carotid body
201.68	Hodgkin's disease, mixed cellularity, involving lymph nodes of multiple sites	C75.5	Malignant neoplasm of aortic body and other paraganglia
201.70	Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites	C75.8	Malignant neoplasm with pluriglandular involvement, unspecified
201.71	Hodgkin's disease, lymphocytic depletion, involving lymph nodes of head, face, and neck	C75.9	Malignant neoplasm of endocrine gland, unspecified
201.72	Hodgkin's disease, lymphocytic depletion, involving intrathoracic lymph nodes	C76.0	Malignant neoplasm of head, face and neck
201.73	Hodgkin's disease, lymphocytic depletion, involving intra-abdominal lymph nodes	C76.1	Malignant neoplasm of thorax
201.74	Hodgkin's disease, lymphocytic depletion, involving lymph nodes of axilla and upper limb	C76.2	Malignant neoplasm of abdomen
201.75	Hodgkin's disease, lymphocytic depletion, involving lymph nodes of inguinal region and lower limb	C76.3	Malignant neoplasm of pelvis
201.76	Hodgkin's disease, lymphocytic depletion, involving intrapelvic lymph nodes	C76.40	Malignant neoplasm of upper limb, unspecified side
201.77	Hodgkin's disease, lymphocytic depletion, involving spleen	C76.41	Malignant neoplasm of right upper limb
201.78	Hodgkin's disease, lymphocytic depletion, involving lymph nodes of multiple sites	C76.42	Malignant neoplasm of left upper limb
201.90	Hodgkin's disease, unspecified type, unspecified site, extranodal and solid organ sites	C76.50	Malignant neoplasm of lower limb, unspecified side
201.91	Hodgkin's disease, unspecified type, involving lymph nodes of head, face, and neck	C76.51	Malignant neoplasm of right lower limb
201.92	Hodgkin's disease, unspecified type, involving intrathoracic lymph nodes	C76.52	Malignant neoplasm of left lower limb
201.93	Hodgkin's disease, unspecified type, involving intra-abdominal lymph nodes	C76.7	Malignant neoplasm of other ill-defined sites
201.94	Hodgkin's disease, unspecified type, involving lymph nodes of axilla and upper limb	C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
201.95	Hodgkin's disease, unspecified type, involving lymph nodes of inguinal region and lower limb	C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
201.96	Hodgkin's disease, unspecified type, involving intrapelvic lymph nodes	C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
201.97	Hodgkin's disease, unspecified type, involving spleen	C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
201.98	Hodgkin's disease, unspecified type, involving lymph nodes of multiple sites	C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
202.00	Nodular lymphoma, unspecified site, extranodal and solid organ sites	C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
202.01	Nodular lymphoma involving lymph nodes of head, face, and neck	C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
202.02	Nodular lymphoma involving intrathoracic lymph nodes	C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified
202.03	Nodular lymphoma involving intra-abdominal lymph nodes	C78.00	Secondary malignant neoplasm of lung, unspecified side
202.04	Nodular lymphoma involving lymph nodes of axilla and upper limb	C78.01	Secondary malignant neoplasm of right lung
202.05	Nodular lymphoma involving lymph nodes of inguinal region and lower limb	C78.02	Secondary malignant neoplasm of left lung
202.06	Nodular lymphoma involving intrapelvic lymph nodes	C78.1	Secondary malignant neoplasm of mediastinum
202.07	Nodular lymphoma involving spleen	C78.2	Secondary malignant neoplasm of pleura
202.08	Nodular lymphoma involving lymph nodes of multiple sites	C78.30	Secondary malignant neoplasm of unspecified respiratory organ
202.10	Mycosis fungoides, unspecified site, extranodal and solid organ sites	C78.39	Secondary malignant neoplasm of other respiratory organs
202.11	Mycosis fungoides involving lymph nodes of head, face, and neck	C78.4	Secondary malignant neoplasm of small intestine
202.12	Mycosis fungoides involving intrathoracic lymph nodes	C78.5	Secondary malignant neoplasm of large intestine and rectum
202.13	Mycosis fungoides involving intra-abdominal lymph nodes	C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
202.14	Mycosis fungoides involving lymph nodes of axilla and upper limb	C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
202.15	Mycosis fungoides involving lymph nodes of inguinal region and lower limb	C78.80	Secondary malignant neoplasm of unspecified digestive organ
202.16	Mycosis fungoides involving intrapelvic lymph nodes	C78.89	Secondary malignant neoplasm of other digestive organs
202.17	Mycosis fungoides involving spleen	C79.00	Secondary malignant neoplasm of kidney and renal pelvis, unspecified side
202.18	Mycosis fungoides involving lymph nodes of multiple sites	C79.01	Secondary malignant neoplasm of right kidney and renal pelvis
202.20	Sezary's disease, unspecified site, extranodal and solid organ sites	C79.02	Secondary malignant neoplasm of left kidney and renal pelvis
202.21	Sezary's disease involving lymph nodes of head, face, and neck	C79.10	Secondary malignant neoplasm of unspecified urinary organs
202.22	Sezary's disease involving intrathoracic lymph nodes	C79.11	Secondary malignant neoplasm of bladder
202.23	Sezary's disease involving intra-abdominal lymph nodes	C79.19	Secondary malignant neoplasm of other urinary organs
202.24	Sezary's disease involving lymph nodes of axilla and upper limb	C79.2	Secondary malignant neoplasm of skin
202.25	Sezary's disease involving lymph nodes of inguinal region and lower limb	C79.31	Secondary malignant neoplasm of brain
202.26	Sezary's disease involving intrapelvic lymph nodes	C79.32	Secondary malignant neoplasm of cerebral meninges
202.27	Sezary's disease involving spleen	C79.40	Secondary malignant neoplasm of unspecified part of nervous system
202.28	Sezary's disease involving lymph nodes of multiple sites	C79.49	Secondary malignant neoplasm of other parts of nervous system
202.30	Malignant histiocytosis, unspecified site, extranodal and solid organ sites	C79.51	Secondary malignant neoplasm of bone
202.31	Malignant histiocytosis involving lymph nodes of head, face, and neck	C79.52	Secondary malignant neoplasm of bone marrow
202.32	Malignant histiocytosis involving intrathoracic lymph nodes	C79.60	Secondary malignant neoplasm of ovary, unspecified side
202.33	Malignant histiocytosis involving intra-abdominal lymph nodes	C79.61	Secondary malignant neoplasm of right ovary
202.34	Malignant histiocytosis involving lymph nodes of axilla and upper limb	C79.62	Secondary malignant neoplasm of left ovary
202.35	Malignant histiocytosis involving lymph nodes of inguinal region and lower limb	C79.70	Secondary malignant neoplasm of adrenal gland, unspecified side
202.36	Malignant histiocytosis involving intrapelvic lymph nodes	C79.71	Secondary malignant neoplasm of right adrenal gland
202.37	Malignant histiocytosis involving spleen	C79.72	Secondary malignant neoplasm of left adrenal gland
202.38	Malignant histiocytosis involving lymph nodes of multiple sites	C79.81	Secondary malignant neoplasm of breast
202.40	Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites	C79.82	Secondary malignant neoplasm of genital organs
202.41	Leukemic reticuloendotheliosis involving lymph nodes of head, face, and neck	C79.89	Secondary malignant neoplasm of other specified sites
202.42	Leukemic reticuloendotheliosis involving intrathoracic lymph nodes	C79.9	Secondary malignant neoplasm of unspecified site
202.43	Leukemic reticuloendotheliosis involving intra-abdominal lymph nodes	C7A.00	Malignant carcinoid tumor of unspecified site
202.44	Leukemic reticuloendotheliosis involving lymph nodes of axilla and upper limb	C7A.010	Malignant carcinoid tumor of the duodenum
202.45	Leukemic reticuloendotheliosis involving lymph nodes of inguinal region and lower limb	C7A.011	Malignant carcinoid tumor of the jejunum

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
202.46	Leukemic reticuloendotheliosis involving intrapelvic lymph nodes	C7A.012	Malignant carcinoid tumor of the ileum
202.47	Leukemic reticuloendotheliosis involving spleen	C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion
202.48	Leukemic reticuloendotheliosis involving lymph nodes of multiple sites	C7A.020	Malignant carcinoid tumor of the appendix
202.50	Letterer-Siwe disease, unspecified site, extranodal and solid organ sites	C7A.021	Malignant carcinoid tumor of the cecum
202.51	Letterer-Siwe disease involving lymph nodes of head, face, and neck	C7A.022	Malignant carcinoid tumor of the ascending colon
202.52	Letterer-Siwe disease involving intrathoracic lymph nodes	C7A.023	Malignant carcinoid tumor of the transverse colon
202.53	Letterer-Siwe disease involving intra-abdominal lymph nodes	C7A.024	Malignant carcinoid tumor of the descending colon
202.54	Letterer-Siwe disease involving lymph nodes of axilla and upper limb	C7A.025	Malignant carcinoid tumor of the sigmoid colon
202.55	Letterer-Siwe disease involving lymph nodes of inguinal region and lower limb	C7A.026	Malignant carcinoid tumor of the rectum
202.56	Letterer-Siwe disease involving intrapelvic lymph nodes	C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion
202.57	Letterer-Siwe disease involving spleen	C7A.090	Malignant carcinoid tumor of the bronchus and lung
202.58	Letterer-Siwe disease involving lymph nodes of multiple sites	C7A.091	Malignant carcinoid tumor of the thymus
202.60	Malignant mast cell tumors, unspecified site, extranodal and solid organ sites	C7A.092	Malignant carcinoid tumor of the stomach
202.61	Malignant mast cell tumors involving lymph nodes of head, face, and neck	C7A.093	Malignant carcinoid tumor of the kidney
202.62	Malignant mast cell tumors involving intrathoracic lymph nodes	C7A.094	Malignant carcinoid tumor of the foregut NOS
202.63	Malignant mast cell tumors involving intra-abdominal lymph nodes	C7A.095	Malignant carcinoid tumor of the midgut NOS
202.64	Malignant mast cell tumors involving lymph nodes of axilla and upper limb	C7A.096	Malignant carcinoid tumor of the hindgut NOS
202.65	Malignant mast cell tumors involving lymph nodes of inguinal region and lower limb	C7A.098	Malignant carcinoid tumors of other sites
202.66	Malignant mast cell tumors involving intrapelvic lymph nodes	C7A.1	Malignant poorly differentiated neuroendocrine tumors
202.67	Malignant mast cell tumors involving spleen	C7A.8	Other malignant neuroendocrine tumors
202.68	Malignant mast cell tumors involving lymph nodes of multiple sites	C7B.00	Secondary carcinoid tumors, unspecified site
202.70	Peripheral T-cell lymphoma, unspecified site, extranodal and solid organ sites	C7B.01	Secondary carcinoid tumors of distant lymph nodes
202.71	Peripheral T-cell lymphoma involving lymph nodes of head, face, and neck	C7B.02	Secondary carcinoid tumors of liver
202.72	Peripheral T-cell lymphoma involving intrathoracic lymph nodes	C7B.03	Secondary carcinoid tumors of bone
202.73	Peripheral T-cell lymphoma involving intra-abdominal lymph nodes	C7B.04	Secondary carcinoid tumors of peritoneum
202.74	Peripheral T-cell lymphoma involving lymph nodes of axilla and upper limb	C7B.09	Secondary carcinoid tumors of other sites
202.75	Peripheral T-cell lymphoma involving lymph nodes of inguinal region and lower limb	C7B.1	Secondary Merkel cell carcinoma
202.76	Peripheral T-cell lymphoma involving intrapelvic lymph nodes	C7B.8	Other secondary neuroendocrine tumors
202.77	Peripheral T-cell lymphoma involving spleen	C80.0	Disseminated malignant neoplasm, unspecified
202.78	Peripheral T-cell lymphoma involving lymph nodes of multiple sites	C80.1	Malignant (primary) neoplasm, unspecified
202.80	Other malignant lymphomas, unspecified site, extranodal and solid organ sites	C80.2	Malignant neoplasm associated with transplanted organ
202.81	Other malignant lymphomas involving lymph nodes of head, face, and neck	C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
202.82	Other malignant lymphomas involving intrathoracic lymph nodes	C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
202.83	Other malignant lymphomas involving intra-abdominal lymph nodes	C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes
202.84	Other malignant lymphomas involving lymph nodes of axilla and upper limb	C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes
202.85	Other malignant lymphomas involving lymph nodes of inguinal region and lower limb	C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb
202.86	Other malignant lymphomas involving intrapelvic lymph nodes	C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
202.87	Other malignant lymphomas involving spleen	C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
202.88	Other malignant lymphomas involving lymph nodes of multiple sites	C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen
202.90	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue, unspecified site, extranodal and solid organ sites	C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
202.91	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of head, face, and neck	C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
202.92	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving intrathoracic lymph nodes	C81.10	Nodular sclerosis classical Hodgkin lymphoma, unspecified site
202.93	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving intra-abdominal lymph nodes	C81.11	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of head, face, and neck
202.94	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of axilla and upper limb	C81.12	Nodular sclerosis classical Hodgkin lymphoma, intrathoracic lymph nodes
202.95	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of inguinal region and lower limb	C81.13	Nodular sclerosis classical Hodgkin lymphoma, intra-abdominal lymph nodes
202.96	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving intrapelvic lymph nodes	C81.14	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
202.97	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving spleen	C81.15	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
202.98	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue involving lymph nodes of multiple sites	C81.16	Nodular sclerosis classical Hodgkin lymphoma, intrapelvic lymph nodes
203.00	Multiple myeloma without mention of having achieved remission	C81.17	Nodular sclerosis classical Hodgkin lymphoma, spleen
203.01	Multiple myeloma in remission	C81.18	Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of multiple sites
203.02	Multiple myeloma in relapse	C81.19	Nodular sclerosis classical Hodgkin lymphoma, extranodal and solid organ sites
203.10	Plasma cell leukemia without mention of having achieved remission	C81.20	Mixed cellularity classical Hodgkin lymphoma, unspecified site
203.11	Plasma cell leukemia in remission	C81.21	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of head, face, and neck
203.12	Plasma cell leukemia in relapse	C81.22	Mixed cellularity classical Hodgkin lymphoma, intrathoracic lymph nodes
203.80	Other immunoproliferative neoplasms without mention of having achieved remission	C81.23	Mixed cellularity classical Hodgkin lymphoma, intra-abdominal lymph nodes
203.81	Other immunoproliferative neoplasms in remission	C81.24	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
203.82	Other immunoproliferative neoplasms in relapse	C81.25	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
204.00	Acute lymphoid leukemia without mention of having achieved remission	C81.26	Mixed cellularity classical Hodgkin lymphoma, intrapelvic lymph nodes
204.01	Acute lymphoid leukemia in remission	C81.27	Mixed cellularity classical Hodgkin lymphoma, spleen
204.02	Lymphoid leukemia, acute in relapse	C81.28	Mixed cellularity classical Hodgkin lymphoma, lymph nodes of multiple sites
204.10	Chronic lymphoid leukemia without mention of having achieved remission	C81.29	Mixed cellularity classical Hodgkin lymphoma, extranodal and solid organ sites
204.11	Chronic lymphoid leukemia in remission	C81.30	Lymphocytic depletion classical Hodgkin lymphoma, unspecified site
204.12	Lymphoid leukemia, chronic in relapse	C81.31	Lymphocytic depletion classical Hodgkin lymphoma, lymph nodes of head, face, and neck
204.20	Subacute lymphoid leukemia without mention of having achieved remission	C81.32	Lymphocytic depletion classical Hodgkin lymphoma, intrathoracic lymph nodes
204.21	Subacute lymphoid leukemia in remission	C81.33	Lymphocytic depletion classical Hodgkin lymphoma, intra-abdominal lymph nodes
204.22	Lymphoid leukemia, subacute in relapse	C81.34	Lymphocytic depletion classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
204.80	Other lymphoid leukemia without mention of having achieved remission	C81.35	Lymphocytic depletion classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
204.81	Other lymphoid leukemia in remission	C81.36	Lymphocytic depletion classical Hodgkin lymphoma, intrapelvic lymph nodes
204.82	Other lymphoid leukemia in relapse	C81.37	Lymphocytic depletion classical Hodgkin lymphoma, spleen

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
204.90	Unspecified lymphoid leukemia without mention of having achieved remission	C81.38	Lymphocytic depletion classical Hodgkin lymphoma, lymph nodes of multiple sites
204.91	Unspecified lymphoid leukemia in remission	C81.39	Lymphocytic depletion classical Hodgkin lymphoma, extranodal and solid organ sites
204.92	Unspecified lymphoid leukemia in relapse	C81.40	Lymphocyte-rich classical Hodgkin lymphoma, unspecified site
205.00	Acute myeloid leukemia without mention of having achieved remission	C81.41	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of head, face, and neck
205.01	Acute myeloid leukemia in remission	C81.42	Lymphocyte-rich classical Hodgkin lymphoma, intrathoracic lymph nodes
205.02	Myeloid leukemia, acute in relapse	C81.43	Lymphocyte-rich classical Hodgkin lymphoma, intra-abdominal lymph nodes
205.10	Chronic myeloid leukemia without mention of having achieved remission	C81.44	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
205.11	Chronic myeloid leukemia in remission	C81.45	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
205.12	Myeloid leukemia, chronic in relapse	C81.46	Lymphocyte-rich classical Hodgkin lymphoma, intrapelvic lymph nodes
205.20	Subacute myeloid leukemia without mention of having achieved remission	C81.47	Lymphocyte-rich classical Hodgkin lymphoma, spleen
205.21	Subacute myeloid leukemia in remission	C81.48	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of multiple sites
205.22	Myeloid leukemia, subacute in relapse	C81.49	Lymphocyte-rich classical Hodgkin lymphoma, extranodal and solid organ sites
205.30	Myeloid sarcoma without mention of having achieved remission	C81.70	Other classical Hodgkin lymphoma, unspecified site
205.31	Myeloid sarcoma in remission	C81.71	Other classical Hodgkin lymphoma, lymph nodes of head, face, and neck
205.32	Myeloid sarcoma in relapse	C81.72	Other classical Hodgkin lymphoma, intrathoracic lymph nodes
205.80	Other myeloid leukemia without mention of having achieved remission	C81.73	Other classical Hodgkin lymphoma, intra-abdominal lymph nodes
205.81	Other myeloid leukemia in remission	C81.74	Other classical Hodgkin lymphoma, lymph nodes of axilla and upper limb
205.82	Other myeloid leukemia in relapse	C81.75	Other classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
205.90	Unspecified myeloid leukemia without mention of having achieved remission	C81.76	Other classical Hodgkin lymphoma, intrapelvic lymph nodes
205.91	Unspecified myeloid leukemia in remission	C81.77	Other classical Hodgkin lymphoma, spleen
205.92	Unspecified myeloid leukemia in relapse	C81.78	Other classical Hodgkin lymphoma, lymph nodes of multiple sites
206.00	Acute monocytic leukemia without mention of having achieved remission	C81.79	Other classical Hodgkin lymphoma, extranodal and solid organ sites
206.01	Acute monocytic leukemia in remission	C81.90	Hodgkin lymphoma, unspecified, unspecified site
206.02	Monocytic leukemia, acute in relapse	C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
206.10	Chronic monocytic leukemia without mention of having achieved remission	C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
206.11	Chronic monocytic leukemia in remission	C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
206.12	Monocytic leukemia, chronic in relapse	C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
206.20	Subacute monocytic leukemia without mention of having achieved remission	C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
206.21	Subacute monocytic leukemia in remission	C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
206.22	Monocytic leukemia, subacute in relapse	C81.97	Hodgkin lymphoma, unspecified, spleen
206.80	Other monocytic leukemia without mention of having achieved remission	C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
206.81	Other monocytic leukemia in remission	C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
206.82	Other monocytic leukemia in relapse	C82.00	Follicular lymphoma grade I, unspecified site
206.90	Unspecified monocytic leukemia without mention of having achieved remission	C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck
206.91	Unspecified monocytic leukemia in remission	C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes
206.92	Unspecified monocytic leukemia in relapse	C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
207.00	Acute erythremia and erythroleukemia without mention of having achieved remission	C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
207.01	Acute erythremia and erythroleukemia in remission	C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb
207.02	Acute erythremia and erythroleukemia in relapse	C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
207.10	Chronic erythremia without mention of having achieved remission	C82.07	Follicular lymphoma grade I, spleen
207.11	Chronic erythremia in remission	C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites
207.12	Chronic erythremia in relapse	C82.09	Follicular lymphoma grade I, extranodal and solid organ sites
207.20	Megakaryocytic leukemia without mention of having achieved remission	C82.10	Follicular lymphoma grade II, unspecified site
207.21	Megakaryocytic leukemia in remission	C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck
207.22	Megakaryocytic leukemia in relapse	C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes
207.80	Other specified leukemia without mention of having achieved remission	C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
207.81	Other specified leukemia in remission	C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
207.82	Other specified leukemia in relapse	C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
208.00	Acute leukemia of unspecified cell type without mention of having achieved remission	C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
208.01	Acute leukemia of unspecified cell type in remission	C82.17	Follicular lymphoma grade II, spleen
208.02	Leukemia of unspecified cell type, acute in relapse	C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites
208.10	Chronic leukemia of unspecified cell type without mention of having achieved remission	C82.19	Follicular lymphoma grade II, extranodal and solid organ sites
208.11	Chronic leukemia of unspecified cell type in remission	C82.20	Follicular lymphoma grade III, unspecified, unspecified site
208.12	Leukemia of unspecified cell type, chronic in relapse	C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck
208.20	Subacute leukemia of unspecified cell type without mention of having achieved remission	C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes
208.21	Subacute leukemia of unspecified cell type in remission	C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
208.22	Leukemia of unspecified cell type, subacute in relapse	C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb
208.80	Other leukemia of unspecified cell type without mention of having achieved remission	C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb
208.81	Other leukemia of unspecified cell type in remission	C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
208.82	Other leukemia of unspecified cell type in relapse	C82.27	Follicular lymphoma grade III, unspecified, spleen
208.90	Unspecified leukemia without mention of having achieved remission	C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
208.91	Unspecified leukemia in remission	C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
208.92	Unspecified leukemia in relapse	C82.30	Follicular lymphoma grade IIIa, unspecified site
209.00	Malignant carcinoid tumor of the small intestine, unspecified portion	C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck
209.01	Malignant carcinoid tumor of the duodenum	C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
209.02	Malignant carcinoid tumor of the jejunum	C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
209.03	Malignant carcinoid tumor of the ileum	C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
209.10	Malignant carcinoid tumor of the large intestine, unspecified portion	C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
209.11	Malignant carcinoid tumor of the appendix	C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
209.12	Malignant carcinoid tumor of the cecum	C82.37	Follicular lymphoma grade IIIa, spleen
209.13	Malignant carcinoid tumor of the ascending colon	C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
209.14	Malignant carcinoid tumor of the transverse colon	C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites
209.15	Malignant carcinoid tumor of the descending colon	C82.40	Follicular lymphoma grade IIIb, unspecified site
209.16	Malignant carcinoid tumor of the sigmoid colon	C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck
209.17	Malignant carcinoid tumor of the rectum	C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
209.20	Malignant carcinoid tumor of unknown primary site	C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
209.21	Malignant carcinoid tumor of the bronchus and lung	C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
209.22	Malignant carcinoid tumor of the thymus	C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
209.23	Malignant carcinoid tumor of the stomach	C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
209.24	Malignant carcinoid tumor of the kidney	C82.47	Follicular lymphoma grade IIIb, spleen
209.25	Malignant carcinoid tumor of the foregut NOS	C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
209.26	Malignant carcinoid tumor of the midgut NOS	C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites
209.27	Malignant carcinoid tumor of the hindgut NOS	C82.50	Diffuse follicle center lymphoma, unspecified site

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
209.29	Malignant carcinoid tumors of other sites	C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck
209.30	Malignant poorly differentiated neuroendocrine carcinoma, any site	C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes
209.31	Merkel cell carcinoma of the face	C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes
209.32	Merkel cell carcinoma of the scalp and neck	C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb
209.33	Merkel cell carcinoma of the upper limb	C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb
209.34	Merkel cell carcinoma of the lower limb	C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes
209.35	Merkel cell carcinoma of the trunk	C82.57	Diffuse follicle center lymphoma, spleen
209.36	Merkel cell carcinoma of other sites	C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites
209.70	Secondary neuroendocrine tumor, unspecified site	C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites
209.71	Secondary neuroendocrine tumor of distant lymph nodes	C82.60	Cutaneous follicle center lymphoma, unspecified site
209.72	Secondary neuroendocrine tumor of liver	C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck
209.73	Secondary neuroendocrine tumor of bone	C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes
209.74	Secondary neuroendocrine tumor of peritoneum	C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes
209.75	Secondary Merkel cell carcinoma	C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb
209.79	Secondary neuroendocrine tumor of other sites	C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb
235.0	Neoplasm of uncertain behavior of major salivary glands	C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
235.1	Neoplasm of uncertain behavior of lip, oral cavity, and pharynx	C82.67	Cutaneous follicle center lymphoma, spleen
235.2	Neoplasm of uncertain behavior of stomach, intestines, and rectum	C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites
235.3	Neoplasm of uncertain behavior of liver and biliary passages	C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites
235.4	Neoplasm of uncertain behavior of retroperitoneum and peritoneum	C82.80	Other types of follicular lymphoma, unspecified site
235.5	Neoplasm of uncertain behavior of other and unspecified digestive organs	C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck
235.6	Neoplasm of uncertain behavior of larynx	C82.82	Other types of follicular lymphoma, lymph nodes of head, face, and neck
235.7	Neoplasm of uncertain behavior of trachea, bronchus, and lung	C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes
235.8	Neoplasm of uncertain behavior of pleura, thymus, and mediastinum	C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb
235.9	Neoplasm of uncertain behavior of other and unspecified respiratory organs	C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb
236.0	Neoplasm of uncertain behavior of uterus	C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
236.1	Neoplasm of uncertain behavior of placenta	C82.87	Other types of follicular lymphoma, spleen
236.2	Neoplasm of uncertain behavior of ovary	C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites
236.3	Neoplasm of uncertain behavior of other and unspecified female genital organs	C82.89	Other types of follicular lymphoma, extranodal and solid organ sites
236.4	Neoplasm of uncertain behavior of testis	C82.90	Follicular lymphoma, unspecified, unspecified site
236.5	Neoplasm of uncertain behavior of prostate	C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
236.6	Neoplasm of uncertain behavior of other and unspecified male genital organs	C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes
236.7	Neoplasm of uncertain behavior of bladder	C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
236.90	Neoplasm of uncertain behavior of urinary organ, unspecified	C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
236.91	Neoplasm of uncertain behavior of kidney and ureter	C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
236.99	Neoplasm of uncertain behavior of other urinary organs	C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes
237.0	Neoplasm of uncertain behavior of pituitary gland and craniopharyngeal duct	C82.97	Follicular lymphoma, unspecified, spleen
237.1	Neoplasm of uncertain behavior of pineal gland	C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites
237.2	Neoplasm of uncertain behavior of adrenal gland	C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites
237.3	Neoplasm of uncertain behavior of paraganglia	C83.00	Small cell B-cell lymphoma, unspecified site
237.4	Neoplasm of uncertain behavior of other and unspecified endocrine glands	C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck
237.5	Neoplasm of uncertain behavior of brain and spinal cord	C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes
237.6	Neoplasm of uncertain behavior of meninges	C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes
237.70	Neurofibromatosis, unspecified	C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb
237.71	Neurofibromatosis, type 1 [von Recklinghausen's disease]	C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb
237.72	Neurofibromatosis, type 2 [acoustic neurofibromatosis]	C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes
237.73	Schwannomatosis	C83.07	Small cell B-cell lymphoma, spleen
237.79	Other neurofibromatosis	C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites
237.9	Neoplasm of uncertain behavior of other and unspecified parts of nervous system	C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites
238.0	Neoplasm of uncertain behavior of bone and articular cartilage	C83.10	Mantle cell lymphoma, unspecified site
238.1	Neoplasm of uncertain behavior of connective and other soft tissue	C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck
238.2	Neoplasm of uncertain behavior of skin	C83.12	Mantle cell lymphoma, intrathoracic lymph nodes
238.3	Neoplasm of uncertain behavior of breast	C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes
238.4	Polycythemia vera	C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb
238.5	Neoplasm of uncertain behavior of histiocytic and mast cells	C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb
238.6	Neoplasm of uncertain behavior of plasma cells	C83.16	Mantle cell lymphoma, intrapelvic lymph nodes
238.71	Essential thrombocythemia	C83.17	Mantle cell lymphoma, spleen
238.72	Low grade myelodysplastic syndrome lesions	C83.18	Mantle cell lymphoma, lymph nodes of multiple sites
238.73	High grade myelodysplastic syndrome lesions	C83.19	Mantle cell lymphoma, extranodal and solid organ sites
238.74	Myelodysplastic syndrome with 5q deletion	C83.30	Diffuse large B-cell lymphoma, unspecified site
238.75	Myelodysplastic syndrome, unspecified	C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
238.76	Myelofibrosis with myeloid metaplasia	C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
238.77	Post-transplant lymphoproliferative disorder (PTLD)	C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
238.79	Other lymphatic and hematopoietic tissues	C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
238.8	Neoplasm of uncertain behavior of other specified sites	C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
238.9	Neoplasm of uncertain behavior, site unspecified	C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
239.0	Neoplasm of unspecified nature of digestive system	C83.37	Diffuse large B-cell lymphoma, spleen
239.1	Neoplasm of unspecified nature of respiratory system	C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
239.2	Neoplasm of unspecified nature of bone, soft tissue, and skin	C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites
239.3	Neoplasm of unspecified nature of breast	C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site
239.4	Neoplasm of unspecified nature of bladder	C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck
239.5	Neoplasm of unspecified nature of other genitourinary organs	C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
239.6	Neoplasm of unspecified nature of brain	C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes
239.7	Neoplasm of unspecified nature of endocrine glands and other parts of nervous system	C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb
239.81	Neoplasm of retina and choroid	C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb
239.89	Neoplasm of unspecified nature of other specified sites	C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
239.9	Neoplasm of unspecified nature, site unspecified	C83.57	Lymphoblastic (diffuse) lymphoma, spleen
		C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
		C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites
		C83.70	Burkitt lymphoma, unspecified site
		C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck
		C83.72	Burkitt lymphoma, intrathoracic lymph nodes
		C83.73	Burkitt lymphoma, intra-abdominal lymph nodes
		C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb
		C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
		C83.76	Burkitt lymphoma, intrapelvic lymph nodes
		C83.77	Burkitt lymphoma, spleen
		C83.78	Burkitt lymphoma, lymph nodes of multiple sites
		C83.79	Burkitt lymphoma, extranodal and solid organ sites
		C83.80	Other non-follicular lymphoma, unspecified site
		C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck
		C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
		C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
		C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
		C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
		C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
		C83.87	Other non-follicular lymphoma, spleen
		C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
		C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
		C83.90	Non-follicular lymphoma, unspecified, unspecified site
		C83.91	Non-follicular lymphoma, unspecified, lymph nodes of head, face, and neck
		C83.92	Non-follicular lymphoma, unspecified, intrathoracic lymph nodes
		C83.93	Non-follicular lymphoma, unspecified, intra-abdominal lymph nodes
		C83.94	Non-follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
		C83.95	Non-follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
		C83.96	Non-follicular lymphoma, unspecified, intrapelvic lymph nodes
		C83.97	Non-follicular lymphoma, unspecified, spleen
		C83.98	Non-follicular lymphoma, unspecified, lymph nodes of multiple sites
		C83.99	Non-follicular lymphoma, unspecified, extranodal and solid organ sites
		C84.00	Mycosis fungoides, unspecified site
		C84.01	Mycosis fungoides, lymph nodes of head, face, and neck
		C84.02	Mycosis fungoides, intrathoracic lymph nodes
		C84.03	Mycosis fungoides, intra-abdominal lymph nodes
		C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
		C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb
		C84.06	Mycosis fungoides, intrapelvic lymph nodes
		C84.07	Mycosis fungoides, spleen
		C84.08	Mycosis fungoides, lymph nodes of multiple sites
		C84.09	Mycosis fungoides, extranodal and solid organ sites
		C84.10	Sezary disease, unspecified site
		C84.11	Sezary disease, lymph nodes of head, face, and neck
		C84.12	Sezary disease, intrathoracic lymph nodes
		C84.13	Sezary disease, intra-abdominal lymph nodes
		C84.14	Sezary disease, lymph nodes of axilla and upper limb
		C84.15	Sezary disease, lymph nodes of inguinal region and lower limb
		C84.16	Sezary disease, intrapelvic lymph nodes
		C84.17	Sezary disease, spleen
		C84.18	Sezary disease, lymph nodes of multiple sites
		C84.19	Sezary disease, extranodal and solid organ sites
		C84.40	Peripheral T-cell lymphoma, not classified, unspecified site
		C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck
		C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes
		C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes
		C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb
		C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb
		C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes
		C84.47	Peripheral T-cell lymphoma, not classified, spleen
		C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites
		C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites
		C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site
		C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck
		C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes
		C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes
		C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb
		C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb
		C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes
		C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen
		C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites
		C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites
		C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site
		C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck
		C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes
		C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes
		C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb
		C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb
		C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes
		C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen
		C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites
		C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
		C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site
		C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck
		C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes
		C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes
		C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb
		C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb
		C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
		C84.97	Mature T/NK-cell lymphomas, unspecified, spleen
		C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites
		C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
		C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site
		C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck
		C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes
		C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes
		C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb
		C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb
		C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes
		C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen
		C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites
		C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites
		C84.Z0	Other mature T/NK-cell lymphomas, unspecified site
		C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
		C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
		C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
		C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
		C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
		C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
		C84.Z7	Other mature T/NK-cell lymphomas, spleen
		C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
		C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites
		C85.10	Unspecified B-cell lymphoma, unspecified site
		C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck
		C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes
		C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes
		C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb
		C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb
		C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes
		C85.17	Unspecified B-cell lymphoma, spleen
		C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites
		C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites
		C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site
		C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck
		C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes
		C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes
		C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb
		C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb
		C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes
		C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen
		C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites
		C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites
		C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site
		C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck
		C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes
		C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
		C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb
		C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
		C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes
		C85.87	Other specified types of non-Hodgkin lymphoma, spleen
		C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites
		C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites
		C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site
		C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
		C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
		C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
		C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
		C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
		C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
		C85.97	Non-Hodgkin lymphoma, unspecified, spleen
		C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
		C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
		C86.0	Extranodal NK/T-cell lymphoma, nasal type
		C86.1	Hepatosplenic T-cell lymphoma
		C86.2	Enteropathy-type (intestinal) T-cell lymphoma
		C86.3	Subcutaneous panniculitis-like T-cell lymphoma
		C86.4	Blastic NK-cell lymphoma
		C86.5	Angioimmunoblastic T-cell lymphoma
		C86.6	Primary cutaneous CD30-positive T-cell proliferations
		C88.0	Waldenstrom macroglobulinemia
		C88.2	Other heavy chain disease
		C88.3	Immunoproliferative small intestinal disease
		C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
		C88.8	Other malignant immunoproliferative diseases
		C88.9	Malignant immunoproliferative disease, unspecified
		C90.00	Multiple myeloma not having achieved remission
		C90.01	Multiple myeloma in remission
		C90.02	Multiple myeloma in relapse
		C90.10	Plasma cell leukemia not having achieved remission
		C90.11	Plasma cell leukemia in remission
		C90.12	Plasma cell leukemia in relapse

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
		C90.20	Extramedullary plasmacytoma not having achieved remission
		C90.21	Extramedullary plasmacytoma in remission
		C90.22	Extramedullary plasmacytoma in relapse
		C90.30	Solitary plasmacytoma not having achieved remission
		C90.31	Solitary plasmacytoma in remission
		C90.32	Solitary plasmacytoma in relapse
		C91.00	Acute lymphoblastic leukemia not having achieved remission
		C91.01	Acute lymphoblastic leukemia, in remission
		C91.02	Acute lymphoblastic leukemia, in relapse
		C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission
		C91.11	Chronic lymphocytic leukemia of B-cell type in remission
		C91.12	Chronic lymphocytic leukemia of B-cell type in relapse
		C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission
		C91.31	Prolymphocytic leukemia of B-cell type, in remission
		C91.32	Prolymphocytic leukemia of B-cell type, in relapse
		C91.40	Hairy cell leukemia not having achieved remission
		C91.41	Hairy cell leukemia, in remission
		C91.42	Hairy cell leukemia, in relapse
		C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
		C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission
		C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse
		C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission
		C91.61	Prolymphocytic leukemia of T-cell type, in remission
		C91.62	Prolymphocytic leukemia of T-cell type, in relapse
		C91.90	Lymphoid leukemia, unspecified not having achieved remission
		C91.91	Lymphoid leukemia, unspecified, in remission
		C91.92	Lymphoid leukemia, unspecified, in relapse
		C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission
		C91.A1	Mature B-cell leukemia Burkitt-type, in remission
		C91.A2	Mature B-cell leukemia Burkitt-type, in relapse
		C91.Z0	Other lymphoid leukemia not having achieved remission
		C91.Z1	Other lymphoid leukemia, in remission
		C91.Z2	Other lymphoid leukemia, in relapse
		C92.00	Acute myeloblastic leukemia, not having achieved remission
		C92.01	Acute myeloblastic leukemia, in remission
		C92.02	Acute myeloblastic leukemia, in relapse
		C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
		C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission
		C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse
		C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission
		C92.21	Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission
		C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse
		C92.30	Myeloid sarcoma, not having achieved remission
		C92.31	Myeloid sarcoma, in remission
		C92.32	Myeloid sarcoma, in relapse
		C92.40	Acute promyelocytic leukemia, not having achieved remission
		C92.41	Acute promyelocytic leukemia, in remission
		C92.42	Acute promyelocytic leukemia, in relapse
		C92.50	Acute myelomonocytic leukemia, not having achieved remission
		C92.51	Acute myelomonocytic leukemia, in remission
		C92.52	Acute myelomonocytic leukemia, in relapse
		C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission
		C92.61	Acute myeloid leukemia with 11q23-abnormality in remission
		C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse
		C92.90	Myeloid leukemia, unspecified, not having achieved remission
		C92.91	Myeloid leukemia, unspecified in remission
		C92.92	Myeloid leukemia, unspecified in relapse
		C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
		C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission
		C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse
		C92.Z0	Other myeloid leukemia not having achieved remission
		C92.Z1	Other myeloid leukemia, in remission
		C92.Z2	Other myeloid leukemia, in relapse
		C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission
		C93.01	Acute monoblastic/monocytic leukemia, in remission
		C93.02	Acute monoblastic/monocytic leukemia, in relapse
		C93.10	Chronic myelomonocytic leukemia not having achieved remission
		C93.11	Chronic myelomonocytic leukemia, in remission
		C93.12	Chronic myelomonocytic leukemia, in relapse
		C93.30	Juvenile myelomonocytic leukemia, not having achieved remission
		C93.31	Juvenile myelomonocytic leukemia, in remission
		C93.32	Juvenile myelomonocytic leukemia, in relapse
		C93.90	Monocytic leukemia, unspecified, not having achieved remission
		C93.91	Monocytic leukemia, unspecified in remission
		C93.92	Monocytic leukemia, unspecified in relapse
		C93.Z0	Other monocytic leukemia, not in remission
		C93.Z1	Other monocytic leukemia, in remission
		C94.00	Acute erythroid leukemia, not having achieved remission
		C94.01	Acute erythroid leukemia, in remission
		C94.02	Acute erythroid leukemia, in relapse
		C94.20	Acute megakaryoblastic leukemia not having achieved remission
		C94.21	Acute megakaryoblastic leukemia, in remission
		C94.22	Acute megakaryoblastic leukemia, in relapse
		C94.30	Mast cell leukemia not having achieved remission
		C94.31	Mast cell leukemia, in remission

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381

Data Element (Value Set Title): Cancer

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
		C94.32	Mast cell leukemia, in relapse
		C94.40	Acute panmyelosis with myelofibrosis not having achieved remission
		C94.41	Acute panmyelosis with myelofibrosis, in remission
		C94.42	Acute panmyelosis with myelofibrosis, in relapse
		C94.6	Myelodysplastic disease, not classified
		C94.80	Other specified leukemias not having achieved remission
		C94.81	Other specified leukemias, in remission
		C94.82	Other specified leukemias, in relapse
		C95.00	Acute leukemia of unspecified cell type not having achieved remission
		C95.01	Acute leukemia of unspecified cell type, in remission
		C95.02	Acute leukemia of unspecified cell type, in relapse
		C95.10	Chronic leukemia of unspecified cell type not having achieved remission
		C95.11	Chronic leukemia of unspecified cell type, in remission
		C95.12	Chronic leukemia of unspecified cell type, in relapse
		C95.90	Leukemia, unspecified not having achieved remission
		C95.91	Leukemia, unspecified, in remission
		C95.92	Leukemia, unspecified, in relapse
		C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
		C96.2	Malignant mast cell tumor
		C96.4	Sarcoma of dendritic cells (accessory cells)
		C96.5	Multifocal and unisystemic Langerhans-cell histiocytosis
		C96.6	Unifocal Langerhans-cell histiocytosis
		C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
		C96.A	Histiocytic sarcoma
		C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
		D37.01	Neoplasm of uncertain behavior of lip
		D37.02	Neoplasm of uncertain behavior of tongue
		D37.030	Neoplasm of uncertain behavior of the parotid salivary glands
		D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands
		D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands
		D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified
		D37.04	Neoplasm of uncertain behavior of the minor salivary glands
		D37.05	Neoplasm of uncertain behavior of pharynx
		D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity
		D37.1	Neoplasm of uncertain behavior of stomach
		D37.2	Neoplasm of uncertain behavior of small intestine
		D37.3	Neoplasm of uncertain behavior of appendix
		D37.4	Neoplasm of uncertain behavior of colon
		D37.5	Neoplasm of uncertain behavior of rectum
		D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts
		D37.7	Neoplasm of uncertain behavior of other digestive organs
		D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified
		D38.0	Neoplasm of uncertain behavior of larynx
		D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung
		D38.2	Neoplasm of uncertain behavior of pleura
		D38.3	Neoplasm of uncertain behavior of mediastinum
		D38.4	Neoplasm of uncertain behavior of thymus
		D38.5	Neoplasm of uncertain behavior of other respiratory organs
		D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified
		D39.0	Neoplasm of uncertain behavior of uterus
		D39.10	Neoplasm of uncertain behavior of ovary, unspecified side
		D39.11	Neoplasm of uncertain behavior of right ovary
		D39.12	Neoplasm of uncertain behavior of left ovary
		D39.2	Neoplasm of uncertain behavior of placenta
		D39.7	Neoplasm of uncertain behavior of other female genital organs
		D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified
		D40.0	Neoplasm of uncertain behavior of prostate
		D40.10	Neoplasm of uncertain behavior of testis, unspecified side
		D40.11	Neoplasm of uncertain behavior of right testis
		D40.12	Neoplasm of uncertain behavior of left testis
		D40.7	Neoplasm of uncertain behavior of other male genital organs
		D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified
		D41.00	Neoplasm of uncertain behavior of kidney, unspecified side
		D41.01	Neoplasm of uncertain behavior of right kidney
		D41.02	Neoplasm of uncertain behavior of left kidney
		D41.10	Neoplasm of uncertain behavior of renal pelvis, unspecified side
		D41.11	Neoplasm of uncertain behavior of right renal pelvis
		D41.12	Neoplasm of uncertain behavior of left renal pelvis
		D41.20	Neoplasm of uncertain behavior of ureter, unspecified side
		D41.21	Neoplasm of uncertain behavior of right ureter
		D41.22	Neoplasm of uncertain behavior of left ureter
		D41.3	Neoplasm of uncertain behavior of urethra
		D41.4	Neoplasm of uncertain behavior of bladder
		D41.7	Neoplasm of uncertain behavior of other urinary organs
		D41.9	Neoplasm of uncertain behavior of urinary organ, unspecified
		D42.0	Neoplasm of uncertain behavior of cerebral meninges
		D42.1	Neoplasm of uncertain behavior of spinal meninges
		D42.9	Neoplasm of uncertain behavior of meninges, unspecified
		D43.0	Neoplasm of uncertain behavior of brain, supratentorial
		D43.1	Neoplasm of uncertain behavior of brain, infratentorial
		D43.2	Neoplasm of uncertain behavior of brain, unspecified
		D43.3	Neoplasm of uncertain behavior of cranial nerves
		D43.4	Neoplasm of uncertain behavior of spinal cord
		D43.7	Neoplasm of uncertain behavior of other parts of central nervous system
		D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified

APPENDIX A: Applicable Diagnosis Codes for Claims/Administrative Data - Measure 0381**Data Element (Value Set Title): Cancer**

ICD-9-CM Code (2011)	ICD-9-CM Code Descriptor (2011)	ICD-10-CM Code (2011)	ICD-10-CM Code Descriptor (2011)
		D44.0	Neoplasm of uncertain behavior of thyroid gland
		D44.10	Neoplasm of uncertain behavior of adrenal gland, unspecified side
		D44.11	Neoplasm of uncertain behavior of right adrenal gland
		D44.12	Neoplasm of uncertain behavior of left adrenal gland
		D44.2	Neoplasm of uncertain behavior of parathyroid gland
		D44.3	Neoplasm of uncertain behavior of pituitary gland
		D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct
		D44.5	Neoplasm of uncertain behavior of pineal gland
		D44.6	Neoplasm of uncertain behavior of carotid body
		D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia
		D44.8	Neoplasm of uncertain behavior with pluriglandular involvement
		D44.9	Neoplasm of uncertain behavior of endocrine gland, unspecified
		D45	Polycythemia vera
		D46.0	Refractory anemia without ring sideroblasts, so stated
		D46.1	Refractory anemia with ring sideroblasts
		D46.20	Refractory anemia with excess of blasts, unspecified
		D46.21	Refractory anemia with excess of blasts 1
		D46.22	Refractory anemia with excess of blasts 2
		D46.4	Refractory anemia, unspecified
		D46.9	Myelodysplastic syndrome, unspecified
		D46.A	Refractory cytopenia with multilineage dysplasia
		D46.B	Refractory cytopenia with multilineage dysplasia and ringed sideroblasts
		D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
		D46.Z	Other myelodysplastic syndromes
		D47.0	Histiocytic and mast cell tumors of uncertain behavior
		D47.1	Chronic myeloproliferative disease
		D47.2	Monoclonal gammopathy
		D47.3	Essential (hemorrhagic) thrombocythemia
		D47.4	Osteomyelofibrosis
		D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
		D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)
		D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
		D48.0	Neoplasm of uncertain behavior of bone and articular cartilage
		D48.1	Neoplasm of uncertain behavior of connective and other soft tissue
		D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system
		D48.3	Neoplasm of uncertain behavior of retroperitoneum
		D48.4	Neoplasm of uncertain behavior of peritoneum
		D48.5	Neoplasm of uncertain behavior of skin
		D48.61	Neoplasm of uncertain behavior of right breast
		D48.62	Neoplasm of uncertain behavior of left breast
		D48.69	Neoplasm of uncertain behavior of unspecified breast
		D48.7	Neoplasm of uncertain behavior of other specified sites
		D48.9	Neoplasm of uncertain behavior, unspecified
		D49.0	Neoplasm of unspecified behavior of digestive system
		D49.1	Neoplasm of unspecified behavior of respiratory system
		D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin
		D49.3	Neoplasm of unspecified behavior of breast
		D49.4	Neoplasm of unspecified behavior of bladder
		D49.5	Neoplasm of unspecified behavior of other genitourinary organs
		D49.6	Neoplasm of unspecified behavior of brain
		D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system
		D49.81	Neoplasm of unspecified behavior of retina and choroid
		D49.89	Neoplasm of unspecified behavior of other specified sites
		D49.9	Neoplasm of unspecified behavior of unspecified site